# <sup>18</sup>F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review

Teruhiko Terasawa<sup>1</sup>, Takashi Nihashi<sup>2</sup>, Tomomitsu Hotta<sup>1</sup>, and Hirokazu Nagai<sup>1</sup>

<sup>1</sup>Clinical Research Center for Blood Diseases, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; and <sup>2</sup>Department of Radiology, National Center for Geriatrics and Gerontology, Obu City, Japan

Although studies have shown that <sup>18</sup>F-FDG PET, when used to assess the response of malignant lymphoma after treatment, has a strong ability to predict relapse, its diagnostic accuracy in clinical practice remains unclear. The aim of this study was to systematically review the diagnostic accuracy of <sup>18</sup>F-FDG PET in detecting residual disease at the completion of first-line therapy of Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL). Methods: We searched relevant articles from 1966 to July 2006 using MEDLINE, EMBASE, SCOPUS, Biological Abstracts, bibliographies, review articles, and textbooks without language restriction. One assessor (for non-English-language studies) or 2 assessors (for English-language studies) independently reviewed each article to abstract relevant study characteristics and results. Relevant individual patient data or subgroup data were provided by the investigators if they were unavailable from the publications. We estimated summary receiver operating characteristic curves and confidence regions for summary sensitivity and specificity. Results: Nineteen studies consisting of 474 HD and 254 aggressive NHL patients were included. These studies had heterogeneity and suboptimal methodologic quality and reporting. Reported ranges for the sensitivity and specificity of <sup>18</sup>F-FDG PET in predicting disease relapse were 0.50-1.00 and 0.67-1.00, respectively, for HD and 0.33-0.77 and 0.82-1.00, respectively, for NHL. These estimates were similar when conventional imaging tests showed a residual mass. For HD studies, the summary receiver operating characteristic curves were similar irrespective of whether a residual mass was detected by conventional tests. Factors explaining the variability of diagnostic estimates were not identified. Conclusion: Although currently available evidence is still limited, <sup>18</sup>F-FDG PET seems to have good diagnostic accuracy for assessing residual HD at the completion of first-line treatment. Clinical data on this use of <sup>18</sup>F-FDG PET for aggressive NHL are more limited. Prospective studies with a more rigorous research design, conduct, and reporting would more reliably reveal the clinical diagnostic accuracy of this imaging modality.

**Key Words:** <sup>18</sup>F-FDG PET; lymphoma; response assessment; residual disease

J Nucl Med 2008; 49:13–21 DOI: 10.2967/jnumed.107.039867

**P**ersistence of a mass after completion of first-line therapy is a common problem in assessing the response of both Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) (1,2). Based on the likelihood of residual disease, clinicians need to proceed to further therapeutic interventions such as applying radiotherapy to the residual mass or salvage chemotherapy with or without high-dose chemotherapy followed by stem cell transplantation. Therefore, more accurate diagnostic tests to distinguish a posttherapy disease mass from fibrosis or scar tissue are needed to reduce the likelihood of unnecessary and potentially toxic therapy (3).

<sup>18</sup>F-FDG PET is a promising functional imaging test for patients with malignant lymphoma and other malignancies and has gained wide use during the last decade (4). Its routine use has been recommended to assess the posttherapy response of HD, especially if CT reveals a residual mass (3). Others have also recommended its use for the same purpose on the basis of its high negative predictive value for HD and high positive predictive value for NHL (5). A recent survey of physicians caring for lymphoma patients found that intended management plans were often changed on the basis of <sup>18</sup>F-FDG PET results (6).

Recently, a systematic review explored the diagnostic accuracy of <sup>18</sup>F-FDG PET for this purpose and assessed the quality of the included studies (7). Similar to studies of diagnostic tests in other medical fields, this review revealed several methodologic problems affecting both the internal and the external validity of the published studies. The authors, however, estimated summary diagnostic accuracy without considering the effect of major methodologic variability on diagnostic tests underlying the original studies. For example, some of the studies included a mix of NHL histologies consisting of indolent, aggressive, and highly

Received Jan. 15, 2007; revision accepted Aug. 18, 2007.

For correspondence or reprints contact: Teruhiko Terasawa, MD, Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, 750 Washington St., Tufts-NEMC #63, Boston, MA 02111.

E-mail: tterasawa@tufts-nemc.org

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

aggressive lymphomas, and others included a mix of patients consisting of those who received first-line therapy and those who received salvage therapy. The diagnostic accuracy estimates reported from these studies have limited external validity and cannot be directly applied to specific clinical scenarios; each distinct histologic subtype has its unique clinical profiles, such as treatment strategies, responses, and prognoses. Also, the review did not consider the different ways that the primary studies presented results (e.g., individual patient vs. each lymphoma lesion, all involved sites vs. only bulky disease, or single vs. multiple inclusions of a patient).

This study was an updated systematic review of the diagnostic accuracy of <sup>18</sup>F-FDG PET in assessing the response of HD and aggressive NHL after first-line therapy, with special emphasis on the methodologic issues discussed above.

#### MATERIALS AND METHODS

#### **Study Identification**

We searched MEDLINE and EMBASE from January 1966 through July 2006 without language restriction. The detailed search strategy can be found in Supplemental Table 1 (supplemental materials are available online only at http://jnm.snmjournals.org). This search was augmented by SCOPUS and Biological Abstracts. We also manually reviewed the reference lists of eligible studies, review articles, and textbooks.

## **Study Selection**

Two of us reviewed the pertinent studies to determine eligibility. We included prospective or retrospective studies evaluating posttherapy response assessment by <sup>18</sup>F-FDG PET exclusively for patients with HD or aggressive NHL followed by clinical followup, with or without pathologic confirmation as a reference standard. We included studies that evaluated at least 10 patients. We considered aggressive NHL to be mantle cell lymphoma; follicular center lymphoma, grade III; diffuse large B-cell lymphoma (DLBCL); primary mediastinal large B-cell lymphoma; peripheral T-cell lymphoma, unspecified; angioimmunoblastic T-cell lymphoma; angiocentric lymphoma; and anaplastic large cell lymphoma, Tand null-cell type by the Revised European-American Classification of Lymphoid Neoplasms (REAL)/World Health Organization classification, or corresponding subcategories for the International Working Formulation classification, the Kiel classification, or the Rappaport classification (8). We included studies of only those patients who completed first-line chemotherapy, radiotherapy, or combined-modality therapy and underwent conventional imaging tests such as CT, ultrasonography, or MRI for posttreatment restaging just before or after undergoing PET. We focused our analysis on studies that reported individual patients as the unit of analysis irrespective of the number of relapses or of the sites of relapse or residual disease, because this is the most appropriate perspective for clinical decision making. We excluded abstracts, editorials, comments, letters, review articles, and case reports. We excluded studies enrolling patients with HIV-associated or posttransplant lymphoproliferative disorders.

Many studies did not meet all the rigorous inclusion criteria but did partially include a relevant patient population. For these studies, we contacted the authors by mail or email to ask for individual patient data or subgroup data relevant to our inclusion criteria. When there was no response within 3 wk, another correspondence was sent. When there was no response to the third communication attempt, we considered the request rejected.

#### **Data Abstraction**

Two independent, board-certified hematologists abstracted relevant data for English-language articles. For non-English-language articles, data were extracted by a single reviewer working with a physician native speaker of the relevant language. We used an abstraction form consisting of items recommended in the Standards for Reporting of Diagnostic Accuracy (9). One nuclear medicine specialist evaluated the technical specifications and quality of the PET procedure by using recommended guidelines (10). The reviewers knew in which journals the studies had been published. Based on the enrollment of participants before PET, we categorized studies into 2 groups: "posttherapy evaluation," or studies that included patients irrespective of restaging results on conventional imaging tests, and "residual mass evaluation," or studies that evaluated only patients for whom visible residual mass lesions were shown on conventional imaging tests. In the posttherapy evaluation, we also abstracted the data on the subgroup of patients who had a residual mass shown on imaging. If the relevant data were unavailable from the published literature, we contacted the authors of the paper to request the subgroup data. Inconsistencies between reviewers were either clarified by the paper authors or resolved by consensus.

# Assessment of Study Quality and Applicability

To evaluate the quality and applicability of the studies included in this review, we used an established quality rating system for diagnostic studies (11) and a recently proposed quality evaluation tool (12). In the established system, we examined 6 aspects of study quality: quality and application of the reference standard, independence of test interpretation, description of patient characteristics, cohort assembly, and sample size. We then rated each study as "a" (the highest quality), "b," "c," or "d" (the lowest quality) according to the predefined score. The recently proposed quality evaluation tool, which was designed exclusively for studies of diagnostic accuracy, comprehensively explores both methodologic quality and reporting. The tool consists of 14 items addressing patient spectrum, reference standard, disease progression bias, partial and differential verification bias, test review bias, clinical review bias, incorporation bias, test execution of both index test and reference standard, study withdrawals, and indeterminate test results.

#### **Data Synthesis and Statistical Analysis**

For each study, we constructed a  $2 \times 2$  contingency table consisting of true-positive, false-positive, false-negative, and truenegative, where all patients were categorized as being PET-positive or -negative and as being positive or negative for disease according to the results determined through <sup>18</sup>F-FDG PET and the reference standard, respectively. We defined as disease-positive a patient who had biopsy-confirmed residual disease or whose disease had relapsed during clinical follow-up. We did not independently combine the sensitivity and specificity of the included studies because this approach does not take into account the interdependence of these 2 test parameters. We instead estimated summary receiver operating characteristic (ROC) curves and elliptic 95% confidence regions of summary sensitivity and specificity by the hierarchical summary ROC method (13). This model is a more sophisticated approach than the conventional linear regression model to compute summary diagnostic measures taking account of variations both within a study and between studies. We fitted the model by using maximumlikelihood estimation implemented in the NLMIXED procedure of SAS/STAT (version 8; SAS Institute) (14). Then, we depicted the summery ROC curves and confidence regions for summary sensitivity and specificity by using Stata (version 8.2.; Stata Corp.) (15). Also, we estimated the area under the curve and the Q\* statistic, the point on the curve where sensitivity equals specificity, as global measures for the summary ROC curves. We explored heterogeneity between studies by visual assessment of ROC plots for the following predetermined items: study design (prospective vs. retrospective), rates of patients with residual mass as found on conventional imaging tests, relapse rates, follow-up period, timing of PET scan after completion of therapy, and publication year. We also performed post hoc subgroup analyses for the items used for the technical specifications of PET and quality assessment.

# RESULTS

# **Study Characteristics**

We included 19 studies: 9 studies (16-24) that met all eligibility criteria and 10 studies (25-34) with relevant published data or with unpublished data obtained by contacting the authors of the paper (Table 1). The detailed process by which articles were selected can be found in the Supplemental Appendix and in Supplemental Figure 1. Because one group of researchers reported a "residual therapy evaluation" for HD and aggressive NHL and a "posttherapy evaluation" exclusively for aggressive NHL-and included in both groups the data on some participants (23,29)-we separately extracted the relevant data. Another group of researchers published an updated "posttherapy evaluation" for HD, with some participants overlapping from the previous report (27,31). We contacted the principal investigator and obtained updated combined results. For 5 studies that reported both HD and aggressive NHL (25-28,30), the contacted investigators provided unpublished subgroup data for each category. As a result, we finally had for further evaluation 15 studies consisting of 474 patients with HD and 8 studies consisting of 254 patients with aggressive NHL (Table 2).

Most studies were retrospective (Table 1). Four studies exclusively evaluated patients for whom a posttherapy visual residual mass was found on conventional imaging tests (25,29,32,34). Generally, patients underwent PET 1–3 mo after completing therapy, but some underwent PET at less than 1 mo. Most studies included both adult and adolescent patients, but 3 studies also included pediatric patients (16,21,24).

For HD studies, nodular sclerosis was the leading histologic subcategory and either ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) plus ABVD or ABV (doxorubicin, bleomycin, vincristine) with or without radiotherapy was the most widely reported first-line treatment (Table 2). In posttherapy evaluations, 35%–72% of patients were found to have a residual mass on conventional imaging (Supplemental Table 2). Relapse rates were similar for both posttherapy evaluations and residual mass evaluations, ranging from 4% to 55% and 0% to 50%, respectively. For aggressive NHL studies, DLBCL was the leading histologic subcategory, and the most widely adopted first-line therapy was CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or comparable doxorubicin-containing regimens with or without radiotherapy (Table 2). In posttherapy evaluations, 26%–56% of patients were found to have a residual mass on conventional imaging (Supplemental Table 2). Relapse rates were 33%–60% for posttherapy evaluations and 33%–67% for residual mass evaluations.

Concerning imaging techniques and technologies, although their reporting was limited, the included studies generally followed the guidelines of the Society of Nuclear Medicine for performing <sup>18</sup>F-FDG PET (Supplemental Table 3). Only a single study used PET/CT (*30*). Most studies adopted qualitative diagnostic criteria: foci of elevated <sup>18</sup>F-FDG uptake unexplained by physiologic uptake. Two studies (*32,34*) also adopted quantitative diagnostic criteria: standardized uptake values (the ratio of <sup>18</sup>F-FDG uptake in tumor sites to that in normal sites). Only 2 studies clearly reported that all the included participants underwent pretherapy PET (*17,23*). Generally, experienced nuclear medicine physicians interpreted the results.

#### Sensitivity, Specificity, and Summary ROC Curves

HD studies reported widely ranging sensitivities and specificities for <sup>18</sup>F-FDG PET. For posttherapy evaluations, sensitivity ranged from 0.50 to 1.00 and specificity ranged from 0.67 to 1.00 (Supplemental Table 2; Fig. 1). For residual mass evaluations, reported estimates had a similarly wide range: 0.43–1.00 for sensitivity and 0.67–1.00 for specificity. The summary ROC curves and confidence regions for summary sensitivity and specificity for posttherapy evaluations and residual mass evaluations were similar (Fig. 2): The area under the curve for the summary ROC curve was 0.94 for posttherapy evaluations and 0.93 for residual mass evaluations, and the Q\* statistic was 0.88 for post-therapy evaluations.

Studies of aggressive NHL also reported a widely ranging sensitivity but a narrower high specificity. For posttherapy evaluations, sensitivity ranged from 0.33 to 0.77 and specificity ranged from 0.82 to 1.00 (Supplemental Table 2; Fig. 1). For residual mass evaluations, sensitivity ranged from 0.33 to 0.87 and specificity ranged from 0.75 to 1.00. We did not perform the metaanalysis because there were too few data points to reliably estimate the summary ROC curves and confidence regions for summary sensitivity and specificity.

# **Investigating Heterogeneity**

We did not identify any clinical or <sup>18</sup>F-FDG PET test characteristics, or any items that assessed the quality and applicability of each study, to explain the heterogeneity of sensitivity and specificity (data not shown).

## **Quality Assessment of Published Studies**

Overall, the quality and reporting of the included studies were limited (Supplemental Table 4), suggesting that they are subject to bias and variation limiting the internal and

Studies Included in the Systematic Review TABLE 1

	Time from therapy completion to PET (mo)	Follow-up (mo)	(mo) c	:		Age (y)	5	Exclusion of patients
Median	an Range	Median	Ð	No. of patients	No. of No. of patients female patients	Median	Range	with PIF or PD during treatment
2	√ 10	13	1–26	34	NR	43	21-73	NR
ЯN	RN	NR or 13*	3-65	24†	33%‡	33 <sup>‡</sup>	20-67	NR
ЯN	1-3	23 or 21*	NR	54	27 (50%)	47	15-80	Yes
RN	$\overline{\wedge}$	NR	~ 12	93 93	RN	NR	RN	NR
RN	$\overline{\nabla}$	38	16-68	32	31 (31%)	NR	RN	NR
ო	NR	9.3#	NR	41†	38%‡	39.6#	RN	NR
5.2	1–87	14	6–39	32	22 (53%)	30	6–65	NR
RN	V	24		32†	36%‡	30‡	18-60	NR
2	0-55	15		48	25 (50%)	38	17–78	NR
-	NR	NR <sup>§</sup>		36	23 (64%)‡	28	13-71	Yes
å#	2-5	50 or 62**		31 <sup>†</sup>	42%‡	31 or 37**	13-70	NR
NR	NR	25		94	44 (47%)‡	30	28-85	NR
4	2–8	45		28	14 (50%)	30.6	16-73	NR
RN	1-3	30		09	33 (45%)	35	11–75	NR
RN	4	28		28	8 (26%)	36	18-76	NR
RN	2-0	32		48	36	NR	∧ 18	NR
-	0-5	35	25-60	54	RN	58	21–79	No
RN	<b>2</b> V	30	7–56	$45^{\dagger}$	37%‡	NR	RN	Yes
ЯN	1-3	21	11-50	93	34 (37%)	47	2-77	NR

\*Patients without or with residual mass, respectively.

<sup>†</sup>Only subset of participants who were evaluated with PET after completion of therapy.

<sup>b</sup>Data abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy.

<sup>§</sup>Some PET scans were taken at the end of salvage therapy.

Some participants underwent PET multiple times.


Teach lymphoma lesion was evaluated as the unit of analysis.

\*Mean.

\*\*Patients with or without bulky mass before therapy, respectively. NR = not reported; PD = progressive disease; PIF = primary induction failure.

le Wit et al. (25)         5         NA         NA         NA         NA         Citation tet al. (75)         5         NA         Citation tet al. (76)         3         22 NS, 7 MC, 2 LP, 1 LD         NA         Citation tet al. (75)         32         22 NS, 6 ML, 4 IV AB         AB         NA         Citation tet al. (77)         32         20 NS, 6 MC, 3 LP, 7 unclassifiable         8 III, 1 III         Citation tet al. (77)         32         21 NS, 3 MC, 1 LD         NA         Citation tet al. (27)         31         23 II, 51 III, 8 IV         AB           Surve stat al. (22)         31         27 NS, 3 MC, 1 LD         NA         NA         Citation tet al. (29)         11 NA         Citation tet al. (20)         NA         Citation tet al. (20)         Citation tet al. (21)         Citation tet al. (21)         Citation tet al. (22)         Citation tet al. (22)         Citation tet al. (22)         Citation tet al. (21)         Citation tet al. (22)         Citation tet al. (22)<	5       NA       NA         (7)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         (7)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 1 III         (77)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 1 III         (27,31)       31       23 II, 5 III, 8 IV       21, 23 II, 15 III, 8 IV         (27,31)       31       27 NS, 3 MC, 1 LD       NA       21, 23 II, 15 III, 8 IV         (27)       33       37       7 NS       3 II, 2 III, 11         (32)       36       NA       8 II, 1 III         (32)       37       NA       8 II, 1 III         (32)       37       NA       8 II, 1 II         (32)       37       NA       8 II, 1 II         (33)       27       NA       8 II, 1 II         (33)       28       27 NS, 3 MC, 1 LD       NA         (34)       NA       8 II, 1 II       NA         (33)       28       27 NS, 3 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         (34)       20       10 NA       NA       NA         (27)       20       20 NC, 3 LP, 2 IN       NA         (21)       21 II, 5 III, 2 III       11, 9 II, 7 III	7 MC, 2 LP, 1 LD NA I MC, 1 unclassifiable 8 II, 4 IIV 6 MC, 3 LP, 7 unclassifiable 31, 23 II, 6 III, 4 IV 3 MC, 1 LD NA MA NA NA 5 MC, 1 LD NA NA 8 I + II, 7 III + IV NA 8 I + II, 7 III, 2 IV NA 8 I + II, 7 III, 2 IV NA 8 I + II, 7 III, 2 IV NA 8 I + II, 35 III, 2 IV NA 8 I + II, 35 III + IV 1 0 1 1, 9 II, 7 III, 2 IV NA 8 I + II, 35 III + IV NA 8 I + II, 35 III + IV NA 8 I + II, 10 III + 10 II 1 1, 9 II, 7 III, 2 IV NA 8 I + II, 10 III + 10 II 1 1, 9 II, 7 III, 2 IV NA 8 I + II, 10 III, 16 IV 1 1, 9 II, 7 III, 2 IV NA 8 I + IV 1 1, 9 II, 7 III, 2 IV NA 8 I + IV 1 1, 9 II, 7 III, 2 IV NA 1 1, 10 III, 10 III + 10 II 1 1, 10 III + 10 II 1 1, 10 III + 10 II 1 1, 3 PTCL	D         D         Chemotherapy ± radiotherapy ± adotherapy ± adoth		HD     MA     Chemotherary is ratiotherary is andotherary in andotherary is	Study	No. of patients*	Histologic class	Pretherapy stage $^{\dagger}$	Type of therapy	
25)       5       NA         (16)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         1       11 (17)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         31       23 (1, 5 li), 6 li), 4 li       8 li, 1 li       8 li, 1 li         31       23 (1, 2 li)       31, 23 li, 6 li), 4 li       8 li, 1 li         31       23 (1, 2 li)       31       23 li, 15 li), 8 li       NA         31       23 (1, 2 li)       15 li       NA       NA       NA         31       23 (1, 2 li)       15 li, 8 li       NA       NA       NA         31       27 NS, 3 MC, 1 LD       NA       NA       NA       NA       NA         31       23 (1, 1 D       NA       NA       NA       NA       NA       NA         31       23 (1, 1 D       NA       NA       NA       NA       NA       NA         30       18       17 NS, 1 MC       21 li       19 lii, 7 lii, 2 li       NA         41       133       21 LD       NA       NA       NA       NA         41       133       21 LD       NA       NA       NA       NA         41       23       23       21	25)       5       NA         (16)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         (17)       32       22 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 1 III         (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 4 IV         (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 4 IV         (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 4 IV         (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 III, 4 IV         (18)       16 (22)       31       21, 23 II, 5 III, 8 IV         (16)       15       NA       NA         (16)       15       NA       NA         (13)       15       NA       NA         (13)       16       17 NS, 1 MC       NA         (13)       21       NA       NA         (13)       21       10       NA         (13)       21       NA       NA         (13)       21       10       NA         (13)       21       11       11         (13)       21       11       11       11         (13)       28       17 NS, 1 MC       11	7 MC, 2 LP, 1 LD NA 1 MC, 1 unclassifiable 8 II, 1 II 6 MC, 3 LP, 7 unclassifiable 31, 23 II, 15 III, 8 IV 3 MC, 1 LD NA 1 MC 1 LD NA 5 MC, 1 LD NA 1 MC 1 LD NA 5 MC, 1 LD NA 5 MC, 1 LD NA 5 MC, 1 LD NA 5 MC, 1 LD NA 6 MC, 3 LP, 3 unclassifiable 21 II, 5 II, 2 IV 1 MC 21 II, 5 II, 2 IV 1 MA 1 MC 21 II, 2 IV 2 MA 1 MA 1 MA 1 MC 21 II, 2 IV 2 MA 1 MA 1 MA 1 MC 21 II, 2 IV 1 MA 1 MA	def Mit et al. (25)         5         NA         Chemotherapy ± radiotherapy = surgery or autobogous           Friedberg et al. (17)         2         2 NS, 1MC, 1 unclassifiable         8 II, 1II         ABN0 ± radiotherapy ± radiotherapy = surgery or autobogous           Friedberg et al. (17)         2         2 NS, 5MC, 1 LD         NM         ABN0 ± radiotherapy ± radiotherapy           Guy et al. (28)         3         2 NS, 5MC, 1 LD         NM         ABN0 ± radiotherapy ± radiotherapy           Guy et al. (28)         3         2 NS, 5MC, 1 LD         NM         ABN0 ± radiotherapy ± radiotherapy           Guy et al. (28)         15         NM         ABN0 ± radiotherapy ± radiotherapy           Mixhael et al. (29)         16         NA         ABN0 ± radiotherapy ± radiotherapy           Mixhael et al. (29)         15         NA         ABN0 ± radiotherapy ± radiotherapy           Mixhael et al. (29)         16         NA         ABN0 ± radiotherapy ± radiotherapy           Mixhael et al. (29)         16         NA         ABN0 ± radiotherapy           Mixhael et al. (29)         28         11, 51, 17, 12, 14         ABN0 ± radiotherapy           Mixhael et al. (29)         28         11, 51, 12, 17         ABN0 ± radiotherapy		Generating         S         NA         Chemotherapy : radiotherapy         calcotherapy : radiotherapy           Fithmart et al. (5)         2         2NS ; MC, 1 unclassifiable         81.11         Chemotherapy : radiotherapy         ranoparation           For et al. (5)         9         7NS. 1 MC, 1 unclassifiable         81.11         Chemotherapy : radiotherapy         ranoparation           For et al. (7)         2         20NS. 6M. 3.1.D         NA         NOP or MOP + ARD : radiotherapy           Missed et al. (2)         3         21.21.15         NA         NOP or MOP + ARD : radiotherapy           Missed et al. (2)         3         21.21.15         NA         NA         NA           Missed et al. (2)         3         NA         NA         NA         NA         NA           Missed et al. (2)         3         NA         NA         NA         NA         NA         NA         NA           Scheder et al. (2)         3         NA         <	₽ ₽					
(16)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         9       7 NS, 1 MC, 1 unclassifiable       8 II, 1 II         9       7 NS, 1 MC, 1 unclassifiable       8 II, 1 II         9       7 NS, 1 MC, 1 unclassifiable       8 II, 1 II         11. (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 II, 1 II         13. (27)       31       27 NS, 3 MC, 1 LD       NA         14. (23)       15       NA       NA         16. NA       NA       NA       NA         (28)       31       NA       NA         (29)       15       NA       NA         (13)       16       NA       NA         (13)       27       10       NA         (13)       28       27 NS, 3 MC, 1 LD       NA         (13)       28       17 NS, 1 MC       21 II, 5 III, 2 IV         (19)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         (21)       28       27 NS, 3 MC a LP, 2 anctassifiable       25 II, 19 III, 16 IV         (21)       28       17 NS, 1 MC       21 II, 2 III, 2 IV         (21)       28       27 NS, 3 MC a LP, 2 anctassifiable       21 II, 2 III, 2 IV         21       21 <td>(16)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         11       17       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 II, 1 III         31       23 II, 53 II, 6 III, 4 IV       31, 23 II, 56 III, 4 IV       31, 23 II, 56 III, 4 IV         31       23 II, 51 III       8 N       31, 23 II, 56 III, 4 IV       21, 23 II, 15 III, 8 IV         31       23 II       23 NC, 1 LD       NA       NA       NA         (28)       31       71 NA       NA       NA         (28)       31       16 NA       NA       NA         (28)       31       17 NS, 1 MC       NA       NA         (13)       27 NS, 5 MC, 1 LD       NA       NA       NA         (29)       28       22 NS, 5 MC, 1 LD       NA       NA         (13)       21       11 NA       81 + II, 7 III + IV         (13)       28       27 NS, 5 MC, 1 LD       NA       NA         (13)       28       28       28       NA       NA         (13)       21       21 II, 5 III, 2 IV       NA       NA         (13)       23       21 II, 16 II, 16 II       NA       21 II, 2 IV         (14)       26       26 II, 20       &lt;</td> <td><ul> <li>7 MC, 2 LP, 1 LD</li> <li>1 MC, 1 unclassifiable</li> <li>6 MC, 3 LP, 7 unclassifiable</li> <li>8 II, 1 II</li> <li>6 MC, 3 LP, 7 unclassifiable</li> <li>8 II, 1 III</li> <li>6 MC, 3 LP, 7 unclassifiable</li> <li>7 II, 5 III, 2 IV</li> <li>8 II + II, 7 III + IV</li> <li>8 II + II, 7 III + IV</li> <li>8 MA</li> <li>9 MC, 3 LP, 3 unclassifiable</li> <li>9 MC, 3 LP, 3 unclassifiable</li> <li>1 II, 5 III, 2 IV</li> <li>1 MA</li> <li>8 MA</li> <li>1 III, 16 IV</li> <li>1 MA</li> <li< td=""><td>Finder et al. (2)         22 NS, 7 MC, 2 LP, 1 LD         NA         Cremenderapy ± radiotherapy ± autopoous           Froe et al. (2)         3         23 NS, 1 MC, 1 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Froe et al. (2)         3         23 NS, 1 MC, 1 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Guay et al. (7)         28         20 NS, 6 MC, 3 LP, 7 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Jancasien et al. (23)         31         23 II, 2 III, 1 V         MOP or ABVD or ABVD or ABVD = radiotherapy           Microsch et al. (23)         31         N N         N N         N N         N N           Microsch et al. (23)         17         N N         N N         N N         N N         N N           Microsch et al. (23)         28         N N         N</td><td></td><td>Finnor et al. (b)         22         2NS, 7 MC, 2 LP, 1 LD         NA         Chemotherapy ± radiotherapy ± sugmy or autoboous           Froeter et al. (b)         9         7 NS, 1 MC, 1 unclassifiable         8.11, 11.         Chemotherapy ± radiotherapy         autobreapy ± radiotherapy           Froeter et al. (p)         31         27 NS, 3 MC, 1 LD         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         31         27 NS, 3 MC, 1 LD         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy           Resolve et al. (p)         30         NA         NA</td><td>de Wit et al. (25)</td><td>5</td><td>NA</td><td>NA</td><td>Chemotherapy ± radiotherapy</td></li<></ul></td>	(16)       32       22 NS, 7 MC, 2 LP, 1 LD       NA         11       17       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 II, 1 III         31       23 II, 53 II, 6 III, 4 IV       31, 23 II, 56 III, 4 IV       31, 23 II, 56 III, 4 IV         31       23 II, 51 III       8 N       31, 23 II, 56 III, 4 IV       21, 23 II, 15 III, 8 IV         31       23 II       23 NC, 1 LD       NA       NA       NA         (28)       31       71 NA       NA       NA         (28)       31       16 NA       NA       NA         (28)       31       17 NS, 1 MC       NA       NA         (13)       27 NS, 5 MC, 1 LD       NA       NA       NA         (29)       28       22 NS, 5 MC, 1 LD       NA       NA         (13)       21       11 NA       81 + II, 7 III + IV         (13)       28       27 NS, 5 MC, 1 LD       NA       NA         (13)       28       28       28       NA       NA         (13)       21       21 II, 5 III, 2 IV       NA       NA         (13)       23       21 II, 16 II, 16 II       NA       21 II, 2 IV         (14)       26       26 II, 20       <	<ul> <li>7 MC, 2 LP, 1 LD</li> <li>1 MC, 1 unclassifiable</li> <li>6 MC, 3 LP, 7 unclassifiable</li> <li>8 II, 1 II</li> <li>6 MC, 3 LP, 7 unclassifiable</li> <li>8 II, 1 III</li> <li>6 MC, 3 LP, 7 unclassifiable</li> <li>7 II, 5 III, 2 IV</li> <li>8 II + II, 7 III + IV</li> <li>8 II + II, 7 III + IV</li> <li>8 MA</li> <li>9 MC, 3 LP, 3 unclassifiable</li> <li>9 MC, 3 LP, 3 unclassifiable</li> <li>1 II, 5 III, 2 IV</li> <li>1 MA</li> <li>8 MA</li> <li>1 III, 16 IV</li> <li>1 MA</li> <li< td=""><td>Finder et al. (2)         22 NS, 7 MC, 2 LP, 1 LD         NA         Cremenderapy ± radiotherapy ± autopoous           Froe et al. (2)         3         23 NS, 1 MC, 1 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Froe et al. (2)         3         23 NS, 1 MC, 1 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Guay et al. (7)         28         20 NS, 6 MC, 3 LP, 7 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Jancasien et al. (23)         31         23 II, 2 III, 1 V         MOP or ABVD or ABVD or ABVD = radiotherapy           Microsch et al. (23)         31         N N         N N         N N         N N           Microsch et al. (23)         17         N N         N N         N N         N N         N N           Microsch et al. (23)         28         N N         N</td><td></td><td>Finnor et al. (b)         22         2NS, 7 MC, 2 LP, 1 LD         NA         Chemotherapy ± radiotherapy ± sugmy or autoboous           Froeter et al. (b)         9         7 NS, 1 MC, 1 unclassifiable         8.11, 11.         Chemotherapy ± radiotherapy         autobreapy ± radiotherapy           Froeter et al. (p)         31         27 NS, 3 MC, 1 LD         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         31         27 NS, 3 MC, 1 LD         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy           Resolve et al. (p)         30         NA         NA</td><td>de Wit et al. (25)</td><td>5</td><td>NA</td><td>NA</td><td>Chemotherapy ± radiotherapy</td></li<></ul>	Finder et al. (2)         22 NS, 7 MC, 2 LP, 1 LD         NA         Cremenderapy ± radiotherapy ± autopoous           Froe et al. (2)         3         23 NS, 1 MC, 1 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Froe et al. (2)         3         23 NS, 1 MC, 1 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Guay et al. (7)         28         20 NS, 6 MC, 3 LP, 7 unclassifiable         8 II, 1 III         Chemotherapy ± radiotherapy           Jancasien et al. (23)         31         23 II, 2 III, 1 V         MOP or ABVD or ABVD or ABVD = radiotherapy           Microsch et al. (23)         31         N N         N N         N N         N N           Microsch et al. (23)         17         N N         N N         N N         N N         N N           Microsch et al. (23)         28         N N         N		Finnor et al. (b)         22         2NS, 7 MC, 2 LP, 1 LD         NA         Chemotherapy ± radiotherapy ± sugmy or autoboous           Froeter et al. (b)         9         7 NS, 1 MC, 1 unclassifiable         8.11, 11.         Chemotherapy ± radiotherapy         autobreapy ± radiotherapy           Froeter et al. (p)         31         27 NS, 3 MC, 1 LD         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         31         27 NS, 3 MC, 1 LD         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy         ardiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy           Resolve et al. (p)         39         NA         NA         NA         NA         ABV D ± radiotherapy           Resolve et al. (p)         30         NA	de Wit et al. (25)	5	NA	NA	Chemotherapy ± radiotherapy	
9       7 NS, 1 MC, 1 unclassifiable       8 II, 1 II         9)       7 NS, 1 MC, 1 unclassifiable       3 I, 23 II, 6 III, 4 IV         9)       48       NA         1. (77)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       3 I, 23 II, 5 III, 8 IV         1. (22)       31       27 NS, 3 MC, 1 LD       NA       NA         2. (23)       31       27 NS, 5 MC, 1 LD       NA       NA         2. (23)       15       NA       NA       NA         2. (23)       15       NA       NA       NA         1. (33)       71       NA       NA       NA         1. (33)       71       NA       NA       NA         2. (29)       15       NA       NA       NA         1. (33)       71       NA       NA       NA         2. (29)       16       45 NS, 9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         2. (21)       28       22 NS, 5 MC, 1 LD       NA       NA         al. (27)       48       17 NS, 1 MC       21 II, 5 III, 2 IV         21       16       17 NS, 1 MC       21 II, 5 III, 2 IV         21       21       21 II, 5 III, 2 III, 2 III, 2 IV       21 II, 5 II, 2 II, 2 IV	9       7 NS, 1 MC, 1 unclassifiable       8 II, 1 II         9       7 NS, 1 MC, 1 unclassifiable       3 I, 23 II, 5 III, 8 IV         9       7 NS, 6 MC, 3 LP, 7 unclassifiable       3 I, 23 II, 15 III, 8 IV         1. (27)       3 2       20 NS, 6 MC, 3 LP, 7 unclassifiable       3 I, 23 II, 15 III, 8 IV         1. (28)       3 7       2 NA       NA       NA         2. (29)       15       NA       NA         2. (29)       15       NA       NA         1. (33)       71       10       NA         1. (33)       71       10       NA         1. (33)       71       10       21         1. (33)       71       10       21       11         1. (33)       71       10       21       11         1. (33)       71       10       21       11         1. (33)       13       10       25       11 <td>IMC, 1 unclassifiable       8 II, 1 II         6 MC, 3 LP, 7 unclassifiable       8 II, 1 II         6 MC, 3 LP, 7 unclassifiable       31, 23 II, 15 III, 8 IV         3 MC, 1 LD       NA         1 MC       NA         6 MC, 3 LP, 7 unclassifiable       2 I, 23 II, 15 III, 8 IV         1 MC       NA         6 MC, 1 LD       NA         1 MC       1 II         6 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         1 MC       3 LP, 3 unclassifiable         1 MC       3 LP, 3 unclassifiable         1 MC       3 LP, 3 unclassifiable         1 MC       3 LP, 19 III, 16 IV         1 MC       21 II, 5 III, 2 IV         NA       NA         8 MC, 3 LP, 2 unclassifiable       21 II, 9 III, 16 IV         1 MC       3 LP, 2 II, 2 II         8 MC, 3 LP, 2 unclassifiable       21 II, 9 III, 16 IV         1 MC       3 LP, 2 II, 2 II         8 MC, 3 LP, 2 unclassifiable       3 I, 5 II, 2 III, 2 IV         8 MA       NA         8 MA       NA         8 MA       NA         8 MA       NA         9 MC, 3 LP, 2 MCL, 7 ALCL HD-like, NA         0 I       NA         0 I</td> <td>For et al. (2)         PMS. 1, IMC. 1 unclassifiable         81. 1 III. Freidenerg et al. (7)         Charangementation           Feidenerg et al. (7)         22         20 NS. 6 MC. 3 LP. 7 unclassifiable         81. 1 III. Freidenerg et al. (7)         Chemotherapy ± radiotherapy ABUO or MOPP + ABVD ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 4 IV         NOPP or ABDO ± radiotherapy ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 4 IV         NOPP or ABDO ± radiotherapy ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 4 IV         NOPP or ABDO = radiotherapy bensitient al. (2)         21. 23 II. 5 III. 2 IV         ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 2 IV         ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 2 IV         ABUO ± radiotherapy bensitient al. (2)         21. 3 II. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 II. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 2 IV         21. 3 III. 2 IV         21. 3 III.</td> <td></td> <td>Foot et al. (2)         9         7 NS, 1 MC, 1 unclassifiable Guard and (13)         81, 1 III Cherobheapt 2 radiotheapt Guard (13)         Turnspatiation a Strong (13)         Strong (13)         Turnspatiation a Strong (13)         Strong (13)         Turnspatiation a Strong (13)         <tht (13)<="" strong="" th=""> <th (13<="" strong="" td=""><td>Filmont et al. (16)</td><td>32</td><td></td><td>NA</td><td>Chemotherapy ± radiotherapy ± surgery or autologous</td></th></tht></td>	IMC, 1 unclassifiable       8 II, 1 II         6 MC, 3 LP, 7 unclassifiable       8 II, 1 II         6 MC, 3 LP, 7 unclassifiable       31, 23 II, 15 III, 8 IV         3 MC, 1 LD       NA         1 MC       NA         6 MC, 3 LP, 7 unclassifiable       2 I, 23 II, 15 III, 8 IV         1 MC       NA         6 MC, 1 LD       NA         1 MC       1 II         6 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         1 MC       3 LP, 3 unclassifiable         1 MC       3 LP, 3 unclassifiable         1 MC       3 LP, 3 unclassifiable         1 MC       3 LP, 19 III, 16 IV         1 MC       21 II, 5 III, 2 IV         NA       NA         8 MC, 3 LP, 2 unclassifiable       21 II, 9 III, 16 IV         1 MC       3 LP, 2 II, 2 II         8 MC, 3 LP, 2 unclassifiable       21 II, 9 III, 16 IV         1 MC       3 LP, 2 II, 2 II         8 MC, 3 LP, 2 unclassifiable       3 I, 5 II, 2 III, 2 IV         8 MA       NA         8 MA       NA         8 MA       NA         8 MA       NA         9 MC, 3 LP, 2 MCL, 7 ALCL HD-like, NA         0 I       NA         0 I	For et al. (2)         PMS. 1, IMC. 1 unclassifiable         81. 1 III. Freidenerg et al. (7)         Charangementation           Feidenerg et al. (7)         22         20 NS. 6 MC. 3 LP. 7 unclassifiable         81. 1 III. Freidenerg et al. (7)         Chemotherapy ± radiotherapy ABUO or MOPP + ABVD ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 4 IV         NOPP or ABDO ± radiotherapy ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 4 IV         NOPP or ABDO ± radiotherapy ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 4 IV         NOPP or ABDO = radiotherapy bensitient al. (2)         21. 23 II. 5 III. 2 IV         ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 2 IV         ABUO ± radiotherapy bensitient al. (2)         21. 23 II. 5 III. 2 IV         ABUO ± radiotherapy bensitient al. (2)         21. 3 II. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 II. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 5 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 2 IV         ABUO ± radiotherapy benotifient al. (2)         21. 3 III. 2 IV         21. 3 III. 2 IV         21. 3 III.		Foot et al. (2)         9         7 NS, 1 MC, 1 unclassifiable Guard and (13)         81, 1 III Cherobheapt 2 radiotheapt Guard (13)         Turnspatiation a Strong (13)         Strong (13)         Turnspatiation a Strong (13)         Strong (13)         Turnspatiation a Strong (13) <tht (13)<="" strong="" th=""> <th (13<="" strong="" td=""><td>Filmont et al. (16)</td><td>32</td><td></td><td>NA</td><td>Chemotherapy ± radiotherapy ± surgery or autologous</td></th></tht>	<td>Filmont et al. (16)</td> <td>32</td> <td></td> <td>NA</td> <td>Chemotherapy ± radiotherapy ± surgery or autologous</td>	Filmont et al. (16)	32		NA	Chemotherapy ± radiotherapy ± surgery or autologous
1       1       7 NS, 1 MC, 1 unclassifiable       8 II, 1 III         1       1       2       1       23 II, 5 III, 8 N         3       2       20 NS, 6 MC, 3 LP, 7 unclassifiable       8 II, 4 IV         3       1       31, 23 II, 15 III, 8 N       21, 23 II, 15 III, 8 N         4       NA       NA       NA         1. (32)       26       NA       NA         1. (33)       15       NA       NA         1. (33)       71       NA       NA         1. (33)       28       22 NS, 5 MC, 1 LD       NA         1. (33)       28       71       NA         1. (30)       18       17 NS, 1 MC       21 II, 5 II, 2 IV         1. (31)       28       17 NS, 1 MC       21 II, 5 II, 2 IV         al. (27)       48       1 P II, 2 IV       NA         al.	1       1       7 NS, 1 MC, 1 unclassifiable       8 II, 1 II         1       21       23 II, 5 III, 8 IV       31         31       27 NS, 3 MC, 1 LD       NA       NA         1       23       27 NS, 3 MC, 1 LD       NA         1       23       27 NS, 3 MC, 1 LD       NA         1       23       15       NA         1       23       15       NA         1       33       27 NS, 3 MC, 1 LD       NA         1       133       15       NA         1       33       15       NA         1       33       27 NS, 3 MC, 1 LD       NA         1       133       71       NA         1       133       71       NA         1       133       71       NA         1       133       28       50 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         1       133       10       11       11       11       11         1       17 NS, 1 MC       21 LP       21 II, 5 III, 2 III, 2 IV       21         1       23       10       12       11       11       11       11       11       11       11	<ul> <li>MC, 1 unclassifiable</li> <li>MC, 1 unclassifiable</li> <li>MC, 3 LP, 7 unclassifiable</li> <li>MA</li> <li>NA</li> &lt;</ul>	Teo et al. (2)         9         7 NS, 1 MC, 1 unclassifiable         8 II, 1 II.         Chemotherapy and cherapy is an each praction and process of a large of al. (1)         2         2 NS, 6 MC, 1 unclassifiable         8 II, 1 II.         ABNO on ABVO ± radiotherapy is a large process of a large of a large of a large process of large proces of large process of large proces of large proces of		Friedberg et al. (7) 2 2 0/NS, 6 MC, 3 LP, 7 unclassifiable 8 II, 1 IIII APP ABUD ± radiotherapy a diotherapy a diotherapy a diotherapy a diotherapy a diotherapy a diotherapy and an an an analyst and an					transplantation	
1. (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       31, 23 II, 6 III, 4 IV         31. (27)       31       27 NS, 3 MC, 1 LD       NA         32       26       NA       NA         31. (32)       26       NA       NA         31. (32)       26       NA       NA         31. (32)       26       NA       NA         27 NS, 3 MC, 1 LD       NA       NA         1. (33)       71       NA       NA         1. (34)       20       NA       11, 9 II, 7 III, 2 IV         al. (37)       35       6       Aggressive by REAL/WHO criteria       NA         al. (27)       48       1 ArtCL       21 II, 5 II, 2 IV       NA         al. (37)       35       5 II, 2 III, 2 IV       NA       A	1. (17)       32       20 NS, 6 MC, 3 LP, 7 unclassifiable       31, 23 II, 6 III, 4 IV         31. (27)       31       27 NS, 3 MC, 1 LD       NA         31. (32)       26       NA       NA         31. (32)       26       NA       NA         31. (32)       27 NS, 3 MC, 1 LD       NA       NA         11. (33)       17 S       NA       NA         11. (33)       71       NA       NA         11. (33)       28       22 NS, 5 MC, 1 LD       NA         (30)       18       17 NS, 1 MC       NA         al. (34)       20       NA       NA         al. (27)       48       NA       11, 9 II, 7 II, 2 IV         al. (27)       48       NA       11, 9 II, 7 II, 2 IV         al. (27)       58       71       11, 0 Griftuse rarge cell       NA	6 MC, 3 LP, 7 unclassifiable 31, 23 II, 15 III, 8 IV 3 MC, 1 LD NA	Guay et al. (7)       32       20 NS, 6 MG, 3 LP, 7 unclassifiable       31, 231, 15 III, 8 IN       NOPP or ABUD ± radiotherapy         Guay et al. (78)       38       NA       21, 231, 15 III, 8 IN       NOPP or ABUD ± radiotherapy         Jensalene et al. (29)       31       21, 231, 15 III, 8 IN       NOPP or ABUD ± radiotherapy         Jensalene et al. (29)       31       NA       Chemotherapy ± radiotherapy         Miknasel et al. (29)       15       NA       NA       Chemotherapy ± radiotherapy         Miknasel et al. (29)       16       NA       NA       Chemotherapy ± radiotherapy         Miknasel et al. (29)       16       NA       NA       NA       Chemotherapy ± radiotherapy         Miknasel et al. (29)       28       22 NS, 5 MC, 1 LD       21, 13 II, 16 IN       ABVD ± radiotherapy         Miknasel et al. (29)       28       22 NS, 5 MC, 1 LD       21, 13 II, 16 IN       ABVD ± radiotherapy         Miknasel et al. (29)       28       28 NG, 1 LD       21, 13 II, 16 IN       ABVD ± radiotherapy         Weinmann et al. (20)       18       31, 16 II, 18 IN       ABVD ± radiotherapy       MA + CEP ± radiotherapy         Weinmann et al. (20)       28       NA       ABVD ± radiotherapy       MA + CEP       Fadiotherapy         Weinmann et al.		Friedbare         21         23         11         41         VI         MOP on ABUO and	Foo et al. <i>(26</i> )	o	7 NS, 1 MC, 1 unclassifiable	8 II, 1 III	Chemotherapy ± radiotherapy	
3)       48       NA         al. (27,31)       31       27 NS, 3 MC, 1 LD       NA         al. (32)       26       NA       NA         (28)       31       27 NS, 3 MC, 1 LD       NA         (28)       31       NA       NA         (29)       15       NA       NA         (13)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       20 NL       NA         (13)       28       20 NL       211, 5 III, 2 IV         (13)       20       NA       NA         al. (27)       48       NA       1, 9 II, 7 III, 2 IV         al. (27)       48       NA       1, 9 II, 7 III, 2 IV         al. (27)       48       NA       1, 9 II, 7 III, 2 IV         al. (27)       48       NA       1, 9 II, 7 III, 2 IV         212       12	3)       48       NA         al. (27,31)       31       27 NS, 3 MC, 1 LD       NA         al. (32)       26       NA       NA         (29)       15       NA       NA         (29)       15       NA       NA         (13)       71       NA       NA         (29)       15       NA       NA         (13)       21       15       NA         (13)       28       22 NS, 5 MC, 1 LD       NA         (13)       28       22 NS, 5 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         (30)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         (31)       28       22 NS, 5 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 7 III, 2 IV         al. (27)       48       NA       NA         al. (27)       48       NA       NA         al. (27)       56       Aggressive by REAL/WHO criteria       31, 5 II, 2 III, 2 IV         al. (27)       48       NA       NA       NA         25)       51       51 II, 13 III, 2 IV       NA         26       51       51 II, 13 III, 2 IV       NA         27       10       10       11, 10 III, 10 III <td>3 MC, 1 LD       NA       NA         NA       NA       NA         NA       NA       NA         S MC, 1 LD       NA       NA         1 MC       21 II, 5 III, 2 IV         9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         1 MC       21 II, 5 III, 2 IV         9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         1 MC       31, 5 II, 2 IV         1 MA       NA         NA       NA         NA       NA         Sive by REAL/WHO criteria       NA         Scl., 8 FL grade 3       NA         Stee by REAL/WHO criteria       NA         Scl., 8 FL/MHO criteria       NA         Stee by REAL/WHO criteria       NA         Stee by REAL/WHO criteria       NA         Scl., 8 ALCL, 7 ALCL HD-like, NA       NA         Scl., 3 PTCL       NA</td> <td>Guy state         48         MA         21, 23 II, 15 III, 8 IV         MOP or ABVD ± fradicitierapy           Jensalen et al. (23)         31         NA         Chemotherapy tarafolineary           Michael et al. (23)         32         NA         ABVD ± radiotherapy           Stratefer al. (30)         58         NA         NA           Stratefer al. (30)         60         45.0.0.1 LD         NA           Stratefer al. (30)         60         45.0.1.0.0         NA           Stratefer al. (30)         70.0.000000000000000000000000000000000</td> <td></td> <td>Guy et al. (2) 48 NA Jenusianer al. (2) 48 NA Jenusianer al. (2) 21 231, 15 III, 51 N. Chemotherapy ± radiotherapy Kerestres et al. (2) 28 NA Michaeler at. (2) 28 NA Michaeler at. (2) 28 NA Michaeler at. (2) 29 NA Michaeler at. (2) 28 NA Michaeler at. (2) 20 NA Michaeler at. (2) 31 J. 11, 19 III, 16 N Michaeler at. (2) 35 20 DLBCL, 8 LQH. J. 24 MA Michaeler at. (2) 31 J. 1, 19 III, 10 NA Michaeler at. (2) 35 DLBCL, 8 LQH. J. ALCL, 2 Michaeler at. (3) 31 J. 1, 19 III, 10 NA Michaeler at. (2) 35 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL A RACL, 7 ALCL, HDHKe, NA Michaeler at. (2</td> <td>Friedberg et al. (17)</td> <td>32</td> <td>4S, 6 MC, 3</td> <td>3 I, 23 II, 6 III, 4 IV</td> <td>ABVD or MOPP + ABVD ± radiotherapy</td>	3 MC, 1 LD       NA       NA         NA       NA       NA         NA       NA       NA         S MC, 1 LD       NA       NA         1 MC       21 II, 5 III, 2 IV         9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         1 MC       21 II, 5 III, 2 IV         9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         1 MC       31, 5 II, 2 IV         1 MA       NA         NA       NA         NA       NA         Sive by REAL/WHO criteria       NA         Scl., 8 FL grade 3       NA         Stee by REAL/WHO criteria       NA         Scl., 8 FL/MHO criteria       NA         Stee by REAL/WHO criteria       NA         Stee by REAL/WHO criteria       NA         Scl., 8 ALCL, 7 ALCL HD-like, NA       NA         Scl., 3 PTCL       NA	Guy state         48         MA         21, 23 II, 15 III, 8 IV         MOP or ABVD ± fradicitierapy           Jensalen et al. (23)         31         NA         Chemotherapy tarafolineary           Michael et al. (23)         32         NA         ABVD ± radiotherapy           Stratefer al. (30)         58         NA         NA           Stratefer al. (30)         60         45.0.0.1 LD         NA           Stratefer al. (30)         60         45.0.1.0.0         NA           Stratefer al. (30)         70.0.000000000000000000000000000000000		Guy et al. (2) 48 NA Jenusianer al. (2) 48 NA Jenusianer al. (2) 21 231, 15 III, 51 N. Chemotherapy ± radiotherapy Kerestres et al. (2) 28 NA Michaeler at. (2) 28 NA Michaeler at. (2) 28 NA Michaeler at. (2) 29 NA Michaeler at. (2) 28 NA Michaeler at. (2) 20 NA Michaeler at. (2) 31 J. 11, 19 III, 16 N Michaeler at. (2) 35 20 DLBCL, 8 LQH. J. 24 MA Michaeler at. (2) 31 J. 1, 19 III, 10 NA Michaeler at. (2) 35 DLBCL, 8 LQH. J. ALCL, 2 Michaeler at. (3) 31 J. 1, 19 III, 10 NA Michaeler at. (2) 35 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL, 8 LQL, 7 ALCL, HDHKe, NA Michaeler at. (2) 5 0 DLBCL A RACL, 7 ALCL, HDHKe, NA Michaeler at. (2	Friedberg et al. (17)	32	4S, 6 MC, 3	3 I, 23 II, 6 III, 4 IV	ABVD or MOPP + ABVD ± radiotherapy	
al. (27,31)       31       27 NS, 3 MC, 1 LD       NA         al. (32)       26       NA       NA         (28)       31       NA       NA         (29)       15       NA       NA         (29)       15       NA       81 + 11, 7 III + IV         (13)       15       NA       81 + 11, 7 III + IV         (13)       21       18       17 NS, 1 MC       81 + 11, 7 III + IV         (19)       28       22 NS, 5 MC, 1 LD       NA       81 + 11, 7 III + IV         (19)       28       22 NS, 5 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         (30)       18       17 NS, 1 MC       21 II, 16 IV       21 II, 16 IV         (31)       28       22 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         al. (27)       48       NA       21 II, 2 IV       NA         al. (27)       48       NA       31, 5 II, 2 IV       NA         25       6       Aggressive by REAL/WHO criteria       NA       11, 9 II, 7 III, 2 IV         26       6       Aggressive by REAL/WHO criteria       NA       13, 5 II, 2 IV       14         26       6       Aggressive by REAL/WHO criteria       NA       13, 11, 2 IV	al. (27,31)       31       27 NS, 3 MC, 1 LD       NA       NA         (28)       31       NA       NA       NA         (29)       15       NA       NA       NA         (29)       15       NA       NA       NA         (13)       15       NA       81 + II, 7 III + IV         (13)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (30)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         (31)       28       22 NS, 5 MC, 1 LD       NA         al. (34)       20       NA       NA         al. (34)       20       NA       NA         al. (27)       48       NA       11, 9 II, 7 III, 2 IV         al. (31)       35       11 diffuse large (1 PTCL       NA         al. (37)       35       47 diffuse large, 1 PTCL       NA         21       13       31, 5 II, 2 III, 2 III, 2 IV       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 II, 10 III + NI <td>3 MC, 1 LD NA NA 5 MC, 1 LD NA 1 MC 9 MC, 3 LP, 3 unclassifiable 21 II, 5 III, 2 IV 1 MA 9 MC, 3 LP, 3 unclassifiable 25 II, 19 III, 16 IV 1, 9 II, 7 III, 2 IV NA SCL, 8 FL grade 3 1, 5 II, 2 II, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 3 I, 5 II, 2 II, 2 IV NA 19 I + II, 35 III + IV NA NA 0 MA 19 I + II, 35 III + N NA NA NA NA NA NA NA NA NA NA NA NA NA</td> <td>Jerusalem et al. (27, 31) 31 27 NS, 3 MC, 1 LD NA Corrections and the argo is all and the al. (28) 31 NA Corrections and the applications and the according and the all (28) 31 NA Correct and (29) 32 NA Correct and (29) 31 NA Correct and (20) 32 Scheder at (28) 32 NA Correct and (28) 31 NA Correct and (28) 22 NS, 5 MC, 1 LD NA Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 23 NO Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 23 N, 1 S, 1 N, 2 N Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 24 Agrees (28) NS, 2 Correct and (28) 24 Agrees (28) NS, 2 Correct and (28) 24 Agrees (28) N, 2 Correct and (28) 26 Correc</td> <td>sei &lt;</td> <td>Name         Canonitareapy beneares rel. (27)         31         27 NS, 3 MG, 1 LD         NA         Components (Components)         Components (Components)         Frankinerapy (Components)         Frankinerapy (Components)</td> <td>Guay et al. (18)</td> <td>48</td> <td>NA</td> <td>2 I, 23 II, 15 III, 8 IV</td> <td>MOPP or ABVD ± radiotherapy</td>	3 MC, 1 LD NA NA 5 MC, 1 LD NA 1 MC 9 MC, 3 LP, 3 unclassifiable 21 II, 5 III, 2 IV 1 MA 9 MC, 3 LP, 3 unclassifiable 25 II, 19 III, 16 IV 1, 9 II, 7 III, 2 IV NA SCL, 8 FL grade 3 1, 5 II, 2 II, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 3 I, 5 II, 2 II, 2 IV NA 19 I + II, 35 III + IV NA NA 0 MA 19 I + II, 35 III + N NA NA NA NA NA NA NA NA NA NA NA NA NA	Jerusalem et al. (27, 31) 31 27 NS, 3 MC, 1 LD NA Corrections and the argo is all and the al. (28) 31 NA Corrections and the applications and the according and the all (28) 31 NA Correct and (29) 32 NA Correct and (29) 31 NA Correct and (20) 32 Scheder at (28) 32 NA Correct and (28) 31 NA Correct and (28) 22 NS, 5 MC, 1 LD NA Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 23 NO Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 23 N, 1 S, 1 N, 2 N Correct and (28) 22 NS, 5 MC, 1 LD Correct and (28) 24 Agrees (28) NS, 2 Correct and (28) 24 Agrees (28) NS, 2 Correct and (28) 24 Agrees (28) N, 2 Correct and (28) 26 Correc	sei <	Name         Canonitareapy beneares rel. (27)         31         27 NS, 3 MG, 1 LD         NA         Components (Components)         Components (Components)         Frankinerapy (Components)	Guay et al. (18)	48	NA	2 I, 23 II, 15 III, 8 IV	MOPP or ABVD ± radiotherapy	
II. (32)       26       NA       NA       NA         (28)       31       NA       NA         (29)       15       NA       NA         (13)       15       NA       NA         (19)       22       NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV         (19)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         (19)       28       22 NS, 9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 16 IV         al. (34)       20       NA       NA         al. (34)       20       NA       NA         al. (37)       35       6       Aggressive by REAL/WHO criteria         25)       6       Aggressive by REAL/WHO criteria       NA         21       11 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 II, 16 N       NA         22)       12       11 diffuse large cell, 4 ALCL, 2 diffuse mixed, 31, 5 II, 2 IV       NA         23)       27 DLBCL, 8 FL grade 3       NA       NA         23)       24       Aggressive VHO criteria       NA         23)       24       Aggressive for thered       19 I+ 11, 35 II + N         230       5       5 ILBCL <t< td=""><td>II. (32)       26       NA       NA       NA         (28)       31       NA       NA       NA         (29)       15       NA       81 + II, 7 III + IV         (133)       71       NA       81 + II, 7 III + IV         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       17 NS, 1 MC       21 II, 5 III, 2 IV         (30)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         (31)       20       13 J MC       3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         (31)       28       22 NS, 5 MC, 1 LD       NA       NA         al. (27)       48       NA       NA       NA         al. (27)       48       NA       11, 9 II, 7 III, 2 IV         al. (27)       35       27 DLBCL, 8 FL grade 3       NA       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 II + II, 35 III + IV       NA         23)       54       47 diffuse mixed, diffuse large cell, 30 I + II, 19 III + NI       NA         23)       55       57 DLBCL, 8 ALCUNO criteria       NA       NA         23)       55       50 DL</td><td>5 MC, 1 LD NA 5 MC, 1 LD 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 5 MC, 1 LD 9 MC, 3 LP, 3 unclassifiable 5 HI, 16 IV 1, 9 H, 7 III, 2 IV NA NA NA NA 1, 9 H, 7 III, 2 IV 1, 9 H, 7 III, 2 IV NA 1, 9 H, 7 III, 2 IV 1, 9 H, 7 III, 2 IV NA 19 H, 19 III, 16 IV 19 H, 7 III, 2 IV NA 19 H, 19 III, 10 III + NI 10 munoblastic 11 N 19 H, 10 III + NI NA 19 H, 10 III + NI NA 19 H, 10 III + NI NA 10 H, 19 III + NI 10 MA NA NA 10 H, 19 III + NI 11 N 10 H, 19 III + NI 12 N 11 N 10 H, 19 III + NI 12 N 10 H, 10 III + NI 13 PTCL</td><td>Kereszbs et al. (22)         25         NA         NA         CMOPP + ABV or C-MOPP + ABV + CEP ± radiotherapy Miknesel et al. (23)         21         NA         NA         Chemotherapy ± radiotherapy         ABV + CEP ± radiotherapy           Miknesel et al. (23)         71         NA         NA         Chemotherapy ± radiotherapy         ABV + CEP ± radiotherapy           Miknesel et al. (29)         28         7.11         NA         Chemotherapy ± radiotherapy         ABV + CEP ± radiotherapy           Miknesel et al. (29)         28         7.03         1.0         NA         Chemotherapy ± radiotherapy           Schaepen et al. (29)         28         28.05, 9.00         3.1.0, 1.0         NA         Chemotherapy ± radiotherapy           Schaepen et al. (29)         28         NA         3.1.0, 1.0         NA         ABV + zediotherapy           Weinmaunt et al. (24)         60         NA         NA         NA         ABV + zediotherapy           Schaepen et al. (29)         28         1.1, 9.11, 1.0         NA         Stanford V or MOPP + ABV. Zediotherapy           Weintaunt al. (21)         35         1.1, 9.11, 1.1, 1.1         NA         Chemotherapy ± radiotherapy           Schaefer et al. (29)         25         1.1, 9.11, 1.1         N         Stanford V or MOPP + ABV. ZeDOM, TOROP     <td>sei Z Z</td><td>Not checker et al. (22) 26 NA NA Checker apy and checker apy and checker apy in the concreance of al. (23) 31 NA Concorter and the apy in the checker approxement at (23) 15 NA NA Checker approxement at (23) 15 NA NA Checker approxement at (23) 16 NA Checker approxement at (23) 17 NA Checker approxement at (23) 18 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 28 NG, 1 LD 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 28 NG, 1 LD 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 20 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at</td><td>Jerusalem et al. (27,31)</td><td></td><td>27 NS, 3 MC, 1 LD</td><td>NA</td><td>Chemotherapy ± radiotherapy</td></td></t<>	II. (32)       26       NA       NA       NA         (28)       31       NA       NA       NA         (29)       15       NA       81 + II, 7 III + IV         (133)       71       NA       81 + II, 7 III + IV         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       28       22 NS, 5 MC, 1 LD       NA         (19)       17 NS, 1 MC       21 II, 5 III, 2 IV         (30)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         (31)       20       13 J MC       3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         (31)       28       22 NS, 5 MC, 1 LD       NA       NA         al. (27)       48       NA       NA       NA         al. (27)       48       NA       11, 9 II, 7 III, 2 IV         al. (27)       35       27 DLBCL, 8 FL grade 3       NA       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 II + II, 35 III + IV       NA         23)       54       47 diffuse mixed, diffuse large cell, 30 I + II, 19 III + NI       NA         23)       55       57 DLBCL, 8 ALCUNO criteria       NA       NA         23)       55       50 DL	5 MC, 1 LD NA 5 MC, 1 LD 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 5 MC, 1 LD 9 MC, 3 LP, 3 unclassifiable 5 HI, 16 IV 1, 9 H, 7 III, 2 IV NA NA NA NA 1, 9 H, 7 III, 2 IV 1, 9 H, 7 III, 2 IV NA 1, 9 H, 7 III, 2 IV 1, 9 H, 7 III, 2 IV NA 19 H, 19 III, 16 IV 19 H, 7 III, 2 IV NA 19 H, 19 III, 10 III + NI 10 munoblastic 11 N 19 H, 10 III + NI NA 19 H, 10 III + NI NA 19 H, 10 III + NI NA 10 H, 19 III + NI 10 MA NA NA 10 H, 19 III + NI 11 N 10 H, 19 III + NI 12 N 11 N 10 H, 19 III + NI 12 N 10 H, 10 III + NI 13 PTCL	Kereszbs et al. (22)         25         NA         NA         CMOPP + ABV or C-MOPP + ABV + CEP ± radiotherapy Miknesel et al. (23)         21         NA         NA         Chemotherapy ± radiotherapy         ABV + CEP ± radiotherapy           Miknesel et al. (23)         71         NA         NA         Chemotherapy ± radiotherapy         ABV + CEP ± radiotherapy           Miknesel et al. (29)         28         7.11         NA         Chemotherapy ± radiotherapy         ABV + CEP ± radiotherapy           Miknesel et al. (29)         28         7.03         1.0         NA         Chemotherapy ± radiotherapy           Schaepen et al. (29)         28         28.05, 9.00         3.1.0, 1.0         NA         Chemotherapy ± radiotherapy           Schaepen et al. (29)         28         NA         3.1.0, 1.0         NA         ABV + zediotherapy           Weinmaunt et al. (24)         60         NA         NA         NA         ABV + zediotherapy           Schaepen et al. (29)         28         1.1, 9.11, 1.0         NA         Stanford V or MOPP + ABV. Zediotherapy           Weintaunt al. (21)         35         1.1, 9.11, 1.1, 1.1         NA         Chemotherapy ± radiotherapy           Schaefer et al. (29)         25         1.1, 9.11, 1.1         N         Stanford V or MOPP + ABV. ZeDOM, TOROP <td>sei Z Z</td> <td>Not checker et al. (22) 26 NA NA Checker apy and checker apy and checker apy in the concreance of al. (23) 31 NA Concorter and the apy in the checker approxement at (23) 15 NA NA Checker approxement at (23) 15 NA NA Checker approxement at (23) 16 NA Checker approxement at (23) 17 NA Checker approxement at (23) 18 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 28 NG, 1 LD 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 28 NG, 1 LD 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 20 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at</td> <td>Jerusalem et al. (27,31)</td> <td></td> <td>27 NS, 3 MC, 1 LD</td> <td>NA</td> <td>Chemotherapy ± radiotherapy</td>	sei Z Z	Not checker et al. (22) 26 NA NA Checker apy and checker apy and checker apy in the concreance of al. (23) 31 NA Concorter and the apy in the checker approxement at (23) 15 NA NA Checker approxement at (23) 15 NA NA Checker approxement at (23) 16 NA Checker approxement at (23) 17 NA Checker approxement at (23) 18 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 28 NG, 1 LD 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 28 NG, 1 LD 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker approxement at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 20 NA ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL and ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. BTL ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at (23) 35 27 DBCL. ADV = radiotherapy is radiotherapy in the checker at (23) 35 20 DBCL. ADV = radiotherapy is radiotherapy is radiotherapy in the checker at	Jerusalem et al. (27,31)		27 NS, 3 MC, 1 LD	NA	Chemotherapy ± radiotherapy	
(28)       31       NA       NA         . (29)       15       NA       81 + II, 7 III + IV         .1. (33)       71       NA       81 + II, 7 III + IV         .1. (33)       71       NA       81 + II, 7 III + IV         .1. (33)       71       NA       81 + II, 7 III + IV         .1. (33)       71       NA       81 + II, 7 III + IV         .1. (30)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV         .1. (34)       20       45 NS, 9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         al. (34)       20       NA       NA       NA         al. (37)       28       Aggressive by REAL/WHO criteria       NA         25)       6       Aggressive by REAL/WHO criteria       NA         21       11 diffuse large, 1 PTCL       NA       NA         21       12       11 diffuse large, 1 PTCL       NA         23       27 DLBCL, 8 FL grade 3       31, 5 I, 2 II, 2 IV         24       35       5 II       91, 7 II, 35 III + IV         23       13       13       11, 91, 11, 35 III + IV         23       24       Aggressive by REAL/WHO criteria       NA         25       5       5 <td><ul> <li>(28) 31 NA</li> <li>(29) 15 NA</li> <li>(30) 15 NA</li> <li>(31) 14 (33)</li> <li>(1) 20</li> <li>(1) 28</li> <li>(2) 22 NS, 5 MC, 1 LD</li> <li>(2) 28</li> <li>(2) 20 NA</li> <li>(3) 28</li> <li>(3) 28</li> <li>(4) 17 NS, 1 MC</li> <li>(2) 20 NA</li> <li>(1) 15 III, 5 III, 2 IV</li> <li>(1) 9 II, 7 III, 9 II, 7 III, 1, 9 II, 7 III, 2 IV</li> <li>(3) 31, 5 II, 2 III, 2 IV</li> <li>(3) 32</li> <li>(3) 35</li> <li>(4) diffuse large, 1 PTCL</li> <li>(1) diffuse large, 1 PTCL</li> <li>(2) 31, 5 II, 2 III, 2 IV</li> <li>(3) 31, 5 II, 2 III, 2 IV</li> <li>(3) 32</li> <li>(3) 31, 5 II, 2 III, 2 IV</li> <li>(3) 32</li> <li>(3) 32</li> <li>(3) 33</li> <li>(3) 15 II, 2 III, 2 IV</li> <li>(3) 31, 5 II, 2 III, 10 III,</li></ul></td> <td>NA 5 MC, 1 LD 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 1 1, 10 III + IVI 1, 1 1, 10 III + IVI 1, 3 PTCL 1, 3 PTCL</td> <td>Mikesch et al. (28)         11         NM         NM         NM         Mikesch et al. (29)         15         NM         NM</td> <td>Sei T</td> <td>Mikosch et al. (29) 31 NA Nicosch et al. (29) 31 NA Nicosch et al. (29) 31 NA Sub tadiotherapy Mikosch et al. (29) 32 SUS 5 MG, 1LD Nicosch et al. (30) 32 SUS 5 MG, 1LD Nicosch et al. (30) 32 SUS 5 MG, 1LD Nicosch et al. (30) 32 SUS 5 MG, 1LD Nicosch et al. (31) 32 Sub tadiotherapy and the approximation of a sub target of al. (31) 32 Nicosch et al. (32) 40 Nicosch et al. (33) 40 Nicosch et al. (34) 42 Nicosch et al. (35) 42 Nicosch et al. (32) 43 Nicosch et al. (32) 44 Nicosch et al. (32) 43 Nicosch et al. (32) 44 Nicosch</td> <td>Keresztes et al. (32)</td> <td>26</td> <td>NA</td> <td>NA</td> <td>C-MOPP + ABVD or C-MOPP + ABV + CEP ± radiotherapy</td>	<ul> <li>(28) 31 NA</li> <li>(29) 15 NA</li> <li>(30) 15 NA</li> <li>(31) 14 (33)</li> <li>(1) 20</li> <li>(1) 28</li> <li>(2) 22 NS, 5 MC, 1 LD</li> <li>(2) 28</li> <li>(2) 20 NA</li> <li>(3) 28</li> <li>(3) 28</li> <li>(4) 17 NS, 1 MC</li> <li>(2) 20 NA</li> <li>(1) 15 III, 5 III, 2 IV</li> <li>(1) 9 II, 7 III, 9 II, 7 III, 1, 9 II, 7 III, 2 IV</li> <li>(3) 31, 5 II, 2 III, 2 IV</li> <li>(3) 32</li> <li>(3) 35</li> <li>(4) diffuse large, 1 PTCL</li> <li>(1) diffuse large, 1 PTCL</li> <li>(2) 31, 5 II, 2 III, 2 IV</li> <li>(3) 31, 5 II, 2 III, 2 IV</li> <li>(3) 32</li> <li>(3) 31, 5 II, 2 III, 2 IV</li> <li>(3) 32</li> <li>(3) 32</li> <li>(3) 33</li> <li>(3) 15 II, 2 III, 2 IV</li> <li>(3) 31, 5 II, 2 III, 10 III,</li></ul>	NA 5 MC, 1 LD 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 1 1, 10 III + IVI 1, 1 1, 10 III + IVI 1, 3 PTCL 1, 3 PTCL	Mikesch et al. (28)         11         NM         NM         NM         Mikesch et al. (29)         15         NM	Sei T	Mikosch et al. (29) 31 NA Nicosch et al. (29) 31 NA Nicosch et al. (29) 31 NA Sub tadiotherapy Mikosch et al. (29) 32 SUS 5 MG, 1LD Nicosch et al. (30) 32 SUS 5 MG, 1LD Nicosch et al. (30) 32 SUS 5 MG, 1LD Nicosch et al. (30) 32 SUS 5 MG, 1LD Nicosch et al. (31) 32 Sub tadiotherapy and the approximation of a sub target of al. (31) 32 Nicosch et al. (32) 40 Nicosch et al. (33) 40 Nicosch et al. (34) 42 Nicosch et al. (35) 42 Nicosch et al. (32) 43 Nicosch et al. (32) 44 Nicosch et al. (32) 43 Nicosch et al. (32) 44 Nicosch	Keresztes et al. (32)	26	NA	NA	C-MOPP + ABVD or C-MOPP + ABV + CEP ± radiotherapy	
. (29)       15       NA       81 + II, 7 III + IV         . (33)       71       NA       NA         . (13)       28       22 NS, 5 MC, 1 LD       NA         . (30)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         . (30)       18       17 NS, 1 MC       21 II, 5 III, 2 IV         . (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         al. (37)       20       NA       NA         al. (37)       20       NA       NA         al. (37)       35       27 DLBCL, 8 FL grade 3       31, 5 II, 2 II, 2 IV         25)       6       Aggressive by REAL/WHO criteria       NA         26)       11 diffuse large, 1 PTCL       NA         27)       31, 5 IL, 2 II, 3 II, 2 IV       NA         26)       12       11 diffuse large, 1 PTCL         27)       13       31, 5 IL, 2 II, 2 IV         28)       27 DLBCL, 8 FL grade 3       31, 5 IL, 1, 35 III + IV         28)       27 DLBCL, 8 FL grade 3       13, 5 IL, 2 IV         28)       28       27 DLBCL, 8 FL Grade 3       16         28)       13       13, 91, 1, 13 III + IV       13, 5 IL, 2 II, 13, 11, 1, 13 III + IV         2	<ul> <li>(29) 15 NA</li> <li>(1) (33) 71 NA</li> <li>(1) (33) 71 NA</li> <li>(1) 28 22 NS, 5 MC, 1 LD</li> <li>(24) 60 45 NS, 9 MC, 3 LP, 3 unclassifiable</li> <li>(24) 60 45 NS, 9 MC, 3 LP, 3 unclassifiable</li> <li>(27) 48 NA</li> <li>(30) 18 17 NS, 1 MC</li> <li>(31) 31, 5 II, 2 IV</li> <li>(32) 6 Aggressive by REAL/WHO criteria</li> <li>(31) 31, 5 II, 2 II, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 11, 9 II, 7 III, 2 IV</li> <li>(31) 35 II, 2 III, 2 IV</li> <li>(32) 22</li> <li>(33) 35 I, 5 II, 2 III, 2 IV</li> <li>(33) 36 G</li> <li>(34) 45 URDUAD criteria</li> <li>(37) 31, 5 II, 2 III, 19 II + 10</li> <li>(38) 55 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>(30) LBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>(30) LBCL, 3 PTCL</li> </ul>	5 MC, 1 LD NA 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 25 II, 19 II, 7 III, 2 IV NA 8 L, 9 II, 7 III, 2 IV NA 11, 9 II, 7 III, 2 IV NA 11, 9 II, 7 III, 2 IV NA 11, 9 II, 7 III, 2 IV NA 19 II, 7 III, 2 IV NA 10 II, 19 III + 10 11	Michael et al. (29)         15         NA         BI + II, 7 III + IV         ABVD ± radiotherapy           Michael et al. (33)         71         Na         Smootheraptical         Chemotheraptical           Michael et al. (33)         71         Na         Smootheraptical         Chemotheraptical           Michael et al. (30)         28         22 NS, 5 MC, 1 LD         NA         Chemotheraptical           Sphaefer et al. (30)         28         22 NS, 5 MC, 1 LD         NA         Chemotheraptical           Sphaefer et al. (30)         28         28 NS, 9 MC, 3 LP, 3 unclassifiable         21 II, 9 II, 7 III, 2 IV         ABVD ± radiotheraptical           Sphaefer et al. (30)         20         NA         NA         Shift 2 IV         NAPD ± radiotheraptical           Mickmann et al. (21)         20         NA         NA         Shift 2 IV         NAPD ± radiotheraptical           Mickmann et al. (21)         20         NA         NA         Shift 2 IV         NAPD ± radiotheraptical           Mickmann et al. (22)         47         7 III, 2 IV         Shift 2 IV         Shift 2 IV         Shift 2 IV           Mickmann et al. (22)         54         47 diffuse large cill + ALCL, 2 diffuse mixed, 191 II + N         25 II, 2 III, 2 IV         Chemotheraptit radiotheraptit	Sei T	Michael et al. (29)         15         MA         B I + II, 7 III + IV         ABVD ± radiotherapy           Repacrier et al. (30)         21         31         21         5         MC           Stabelier et al. (30)         28         21, 5         NA         ABVD ± radiotherapy           Stabelier et al. (30)         28         15, 5         NC, 1LD         211, 5         NL         ABVD ± radiotherapy           Stabelier et al. (30)         28         7, NS, 1, MC         20         NA         ABVD ± radiotherapy           Stabelier et al. (20)         60         45         NS, 9         MC, 3 LP, 3         arclassifiable         251, 11, 5         NL         ABVD, ± radiotherapy           Weihrauch et al. (24)         20         NA         ABVD, ± radiotherapy         aradiotherapy         aradiotherapy         aradiotherapy           Weihrauch et al. (25)         24         Aggressive by REALWHO criteria         NA         ABVD, ± radiotherapy         aradiotherapy           Jurveid et al. (25)         24         Aggressive by REALWHO criteria         NA         Chemotherapy ± radiotherapy           Jurveid et al. (25)         24         Aggressive by REALWHO criteria         NA         Chemotherapy ± radiotherapy           Jurveid et al. (26)         55 <t< td=""><td>Mikosch et al. (28)</td><td>31</td><td>NA</td><td>NA</td><td>Chemotherapy ± radiotherapy</td></t<>	Mikosch et al. (28)	31	NA	NA	Chemotherapy ± radiotherapy	
I. (33)       71       NA         (19)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV         . (30)       18       17 NS, 1 MC       21 II, 5 III, 5 III, 2 IV         . (30)       18       17 NS, 1 MC       21 II, 5 III, 5 III, 2 IV         . (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         al. (34)       20       NA       NA         al. (37)       20       NA       NA         al. (37)       26       Aggressive by REAL/WHO criteria       31, 5 II, 2 II, 2 IV         25)       6       Aggressive by REAL/WHO criteria       31, 5 II, 2 II, 2 IV         26)       11 diffuse large, 1 PTCL       NA       NA         21       31, 5 II, 2 IV       NA         26)       54       47 diffuse large, 1 PTCL       NA         27)       35       27 DLBCL, 8 FL grade 3       NA         28)       27 DLBCL, 8 FL grade 3       NA       NA         28)       27 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 II, + II, 35 III + IV       NA         28)       27 DLBCL, 8 FL WHO criteria       NA       NA         29)       58       27 DLBCL, 8 FL WHO criteria       NA         28)       58<	I. (33)       71       NA       NA         (19)       28       22 NS, 5 MC, 1 LD       21 II, 5 II, 2 IV         . (30)       18       17 NS, 1 MC       21 II, 5 II, 2 IV         . (31)       20       45 NS, 9 MC, 3 LP, 3 unclassifiable       21 II, 5 II, 2 IV         al. (34)       20       NA       25 NS, 9 MC, 3 LP, 2 unclassifiable       25 II, 19 III, 16 IV         al. (27)       48       NA       NA       NA         al. (37)       20       NA       NA         25)       6       Aggressive by REAL/WHO criteria       21 I, 1, 9 II, 7 III, 2 IV         25)       12       11 diffuse large, 1 PTCL       NA         21       31, 5 II, 2 diffuse mixed,       31, 5 II, 2 III, 2 IV         21       31       5 II, 2 III, 2 IV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed,         23)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed,         23)       54       7 aggressive by REAL/WHO criteria         23)       54       7 aggressive diffuse mixed,         23)       54       7 aggressive diffuse mixed,         23)       55       50 LBCL, 7 ALCL HD-like,         34       58 MCL, 3 PTCL       NA	5 MC, 1 LD 1 MC 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 1, 19 II + 1VI cell immunoblastic 1, 3 PTCL NA NA 1, 1, 10 III + NI	Mocikova et al. (33)         71         NA         Mocikova et al. (32)         23         27 NS, 5 MC, 1 LD         NA         Chemotherapy is adiotherapy           Bigacci et al. (30)         28         22 NS, 5 MC, 1 LD         NA         NA         NA         NA         NA         Stanford V or MOPP + ABV ± radiotherapy           Spaepen et al. (24)         60         45 NS, 9 MC, 3 LP, 3 unclassifiable         25 II, 19 III, 16 N         Stanford V or MOPP + ABV ± radiotherapy           Weihrauch et al. (23)         20         NA         NA         NA         21 II, 2 IV         ABVD, 5 - MODP + ABV ± radiotherapy           Weihrauch et al. (23)         20         45         NA         NA         NA         ABVD, 5 - MODP + ABV ± radiotherapy           Weikrauch et al. (23)         6         Agressive by FRAL/MHO criteria         NA         ABVD, 5 - MODP + ABV ± radiotherapy           Geo kut et al. (23)         5         4         7 diffuse large cell, 4 ALCL, 2 diffuse         NA         Chemotherapy ± radiotherapy           Juveid et al. (23)         5         4         7 diffuse large cell, 4 ALCL, 2 diffuse         NA         Chemotherapy ± radiotherapy           Juveid et al. (23)         5         4         7 diffuse large cell, 4 ALCL, 2 diffuse         NA         Chemotherapy ± radiotherapy           Ju	Seil T	Mocieva et al. (3) 71 NA Chemotherapy radiotherapy addotherapy addotherapy radiotherapy radiotherapy tradiotherapy tradi ango contradiotherapy tradiotherapy tradiotherapy	Mikhaeel et al. (29)	15	NA	8 I + II, 7 III + IV	ABVD ± radiotherapy	
(19)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV         . (30)       18       17 NS, 1 MC       NA         . (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       21 II, 5 III, 2 IV         al. (21)       48       NA       25 II, 19 II, 7 III, 2 IV         al. (21)       48       NA       25 II, 9 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (21)       35       27 DLBCL, 8 FL grade 3       NA         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell, MA         23)       51 BCL, 3 PLCL, 7 ALCL HD-like, NA         55 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       50 I + II, 19 III + IVII         56 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       50 I + II, 19 III + IVII	(19)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV         . (30)       18       17 NS, 1 MC       NA         . (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 9 III, 16 IV         al. (34)       20       NA       25 NS, 9 MC, 3 LP, 2 unclassifiable       25 II, 9 III, 16 IV         al. (34)       20       NA       NA       25 II, 19 III, 2 IV         al. (37)       26       Aggressive by REAL/WHO criteria       25 II, 19 II, 7 III, 2 IV         25)       6       Aggressive by REAL/WHO criteria       NA         21       11 diffuse large, 1 PTCL       NA       NA         21       31, 5 II, 2 II       NA       NA         27       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + N         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + N         28)       . (28)       . (28)       NA         27)       . (28)       . (28)       NA         28)       . (28)       . (30)       . (19 II + II, 19 III + N)I         28)       . (28)       . (28)       . (1000 lastic)         29)       . (28)       . (28)       . (1000 lastic)         21       . (28) <td>5 MC, 1 LD 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 1, 9 II, 7 III, 2 IV 1, 1 1, 19 III + IVI cell immunoblastic NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA 1, 3 PTCL</td> <td>Rigacci et al. (19)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV       ABVD ± radiotherapy         Schaefer et al. (29)       16       17 NS, 1 MC       NA       NA       NA         Spearen et al. (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV       ABVD ± radiotherapy         Weinmann et al. (21)       20       NA       NA       NA       ABVD ± radiotherapy         Workmann et al. (22)       20       NA       NA       ABVD ± radiotherapy         Workmann et al. (22)       20       NA       NA       ABVD ± radiotherapy         Workmann et al. (25)       12       11 diffuse large, 1 PTCL       ABVD       NA         Joursalem et al. (22)       12       11 diffuse large, 1 PTCL       NA       Chemotherapy ± radiotherapy         Joursalem et al. (23)       25       DIBCL, 8 FL grade 3       NA       NA       Chemotherapy ± radiotherapy         Joursalem et al. (23)       27       DIBCL, 8 FL grade 3       NA       Chemotherapy ± radiotherapy         Microsot et al. (24)       5       5       NA       NA       Chemotherapy ± radiotherapy         Microsot et al. (23)       26       5       11 light       NA       27 CHOP; 29 POMACE-CytaBOM, 1 CNOP         Microsot</td> <td>Seil Tr</td> <td>Rigacci et al. (0)         28         2 NG, 5 MG, 1 LD         21 II, 5 III, 2 IV         ABVD ± radiotherapy Nehmauch et al. (20)         28         17 NS, 1 MC         ABVD ± radiotherapy Nehmauch et al. (20)         28         19 II, 7 III, 2 IV         ABVD ± radiotherapy Nehmauch et al. (20)         28         19 II, 7 III, 2 IV         ABVD ± radiotherapy Nehmauch et al. (20)         28         19 II, 7 III, 2 IV         ABVD, c-MOP + ABV ± radiotherapy Network         28         10 III, 9 II, 7 III, 2 IV         ABVD, c-MOP + ABV ± radiotherapy ABVD, c-MOP + ABV, or BEACOPP ± radiotherapy tendenterap ± radiotherapy           Werkmauch et al. (22)         5         7 0 ENDL, 8 FALWHO oriteta         NA         Chemotherapy ± radiotherapy tendiotherapy ± radiotherapy           Jerosation tal. (23)         5         7 0 ENDL, 8 FALWHO oriteta         NA         Chemotherapy ± radiotherapy           Jerosation tal. (23)         54         4 7 diffuse large call ALCL.         2 fiftuse mixed.         19 I + II, 35 II + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Jerosation tal. (23)         54         4 7 diffuse large call ALCL.         2 III + II, 35 II + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Junedict et al. (23)         54         4 7 diffuse large call         NA         Chemotherapy ± radiotherapy           Miknaeel et al. (23)         54         7 3 diffuse large call         10 I II, I II II + II</td> <td>Mocikova et al. (33)</td> <td>71</td> <td>NA</td> <td>NA</td> <td>Chemotherapy ± radiotherapy</td>	5 MC, 1 LD 1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 1, 9 II, 7 III, 2 IV NA 1, 9 II, 7 III, 2 IV 1, 9 II, 7 III, 2 IV NA 1, 1, 9 II, 7 III, 2 IV 1, 1 1, 19 III + IVI cell immunoblastic NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA 1, 3 PTCL	Rigacci et al. (19)       28       22 NS, 5 MC, 1 LD       21 II, 5 III, 2 IV       ABVD ± radiotherapy         Schaefer et al. (29)       16       17 NS, 1 MC       NA       NA       NA         Spearen et al. (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV       ABVD ± radiotherapy         Weinmann et al. (21)       20       NA       NA       NA       ABVD ± radiotherapy         Workmann et al. (22)       20       NA       NA       ABVD ± radiotherapy         Workmann et al. (22)       20       NA       NA       ABVD ± radiotherapy         Workmann et al. (25)       12       11 diffuse large, 1 PTCL       ABVD       NA         Joursalem et al. (22)       12       11 diffuse large, 1 PTCL       NA       Chemotherapy ± radiotherapy         Joursalem et al. (23)       25       DIBCL, 8 FL grade 3       NA       NA       Chemotherapy ± radiotherapy         Joursalem et al. (23)       27       DIBCL, 8 FL grade 3       NA       Chemotherapy ± radiotherapy         Microsot et al. (24)       5       5       NA       NA       Chemotherapy ± radiotherapy         Microsot et al. (23)       26       5       11 light       NA       27 CHOP; 29 POMACE-CytaBOM, 1 CNOP         Microsot	Seil Tr	Rigacci et al. (0)         28         2 NG, 5 MG, 1 LD         21 II, 5 III, 2 IV         ABVD ± radiotherapy Nehmauch et al. (20)         28         17 NS, 1 MC         ABVD ± radiotherapy Nehmauch et al. (20)         28         19 II, 7 III, 2 IV         ABVD ± radiotherapy Nehmauch et al. (20)         28         19 II, 7 III, 2 IV         ABVD ± radiotherapy Nehmauch et al. (20)         28         19 II, 7 III, 2 IV         ABVD, c-MOP + ABV ± radiotherapy Network         28         10 III, 9 II, 7 III, 2 IV         ABVD, c-MOP + ABV ± radiotherapy ABVD, c-MOP + ABV, or BEACOPP ± radiotherapy tendenterap ± radiotherapy           Werkmauch et al. (22)         5         7 0 ENDL, 8 FALWHO oriteta         NA         Chemotherapy ± radiotherapy tendiotherapy ± radiotherapy           Jerosation tal. (23)         5         7 0 ENDL, 8 FALWHO oriteta         NA         Chemotherapy ± radiotherapy           Jerosation tal. (23)         54         4 7 diffuse large call ALCL.         2 fiftuse mixed.         19 I + II, 35 II + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Jerosation tal. (23)         54         4 7 diffuse large call ALCL.         2 III + II, 35 II + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Junedict et al. (23)         54         4 7 diffuse large call         NA         Chemotherapy ± radiotherapy           Miknaeel et al. (23)         54         7 3 diffuse large call         10 I II, I II II + II	Mocikova et al. (33)	71	NA	NA	Chemotherapy ± radiotherapy	
. (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         . (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         al. (21)       48       NA       20       NA         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (21)       20       NA       11, 9 II, 7 III, 2 IV         al. (21)       36       Aggressive by REAL/WHO criteria       NA         25)       6       Aggressive by REAL/WHO criteria       NA         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell, 7 ALCL, 2 diffuse large cell, 30 I + II, 19 III + IVII         (23)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA         (30)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA         5 MCL, 3 PTCL       7 ALCL HD-like, NA	. (30)       18       17 NS, 1 MC       NA         . (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 III, 16 IV         al. (34)       20       NA       11, 9 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (31)       20       NA       NA         25)       6       Aggressive by REAL/WHO criteria       21, 10 II, 7 III, 2 IV         25)       12       11 diffuse large, 1 PTCL       NA         21       31       5 II, 2 III, 2 IV         25       27 DLBCL, 8 FL grade 3       NA         22)       11 diffuse large, 1 PTCL       NA         21       13 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + N         22)       1       angioimmunoblastic T-cell         (23)       24       Aggressive" (diffuse mixed, diffuse large cell, 30 I + II, 19 III + NI         (23)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA         . (24)       5       5 MCL, 3 PTCL         . (24)       5 MCL, 3 PTCL       NA	1 MC 9 MC, 3 LP, 3 unclassifiable 9 MC, 3 LP, 3 unclassifiable sive by REAL/WHO criteria sive by REAL/WHO criteria as large, 1 PTCL 8CL, 8 FL grade 3 ise large cell, 4 ALCL, 2 diffuse mixed, gioimmunoblastic T-cell sive by REAL/WHO criteria sive by REAL/WHO criteria sive by REAL/WHO criteria sive by REAL/WHO criteria Sive by REAL/WHO criteria as a struct cell immunoblastic) CL 8 ALCL, 7 ALCL HD-like, NA 3 1, 5 11, 2 11, 2 1V NA 19 1 + 11, 35 11 + 1V NA 19 1 + 11, 35 11 + 1V NA 19 1 + 11, 19 11 + 1V <sup>II</sup> cell immunoblastic) CL 8 ALCL, 7 ALCL HD-like, NA	Schaefer et al. (20)       13       17 NS, 1 MC       NA         Speapen et al. (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 II, 16 IV       Stanford V or MOPP + ABV ± radiotherapy         Speapen et al. (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 II, 7 III, 2 IV       Stanford V or MOPP + ABV ± radiotherapy         Weinnauch et al. (27)       20       NA       NA       ABP       ABPC, C-MOPP + ABV, or BEACOPP ± radiotherapy         Weinnauch et al. (27)       20       NA       NA       ABP       ABPC, C-MOPP + ABV, or BEACOPP ± radiotherapy         Boressive NHL       6       Agpressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         GeViel et al. (29)       12       11 diffuse large of I, PTCL, alfuse mixed, 19 I, I, 35 II I, I, V       Chemotherapy ± radiotherapy         Jurveid et al. (29)       24       Aggressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         Mikosch et al. (29)       5       21 URU       NA       Chemotherapy ± radiotherapy         Mikosch et al. (29)       5       21 URU       NA       Chemotherapy ± radiotherapy         Mikosch et al. (29)       5       21 H, II, 18 II H, NI       Radiotherapy       21 H, IOP         Mikosch et al. (20)       5       21 H, II, 21 H,	Seil Tr	Sparefer et al. (20) 16 17 NS, 1 MC MA NA Natrona et al. (21) 20 Natronal variable 25 II, 19 III, 16 IV Stanford V or MOPP + ABV ± radiotherapy <sup>1</sup> Werkmann et al. (22) 20 NA Natronal et al. (23) 20 NA NA Chemotherapy ± radiotherapy = 7 Natronal variable 11, 9 II, 7 III, 2 IV GPOH+ID 955 GPO	Rigacci et al. (19)	28		21 II, 5 III, 2 IV	ABVD ± radiotherapy	
(24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 II, 7 III, 2 IV         al. (21)       20       NA       11, 9 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (21)       20       NA       11, 9 II, 7 III, 2 IV         al. (21)       26       Aggressive by REAL/WHO criteria       21, 19 II, 7 III, 2 IV         25)       6       Aggressive by REAL/WHO criteria       NA         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV         22)       54       47 diffuse large cell       NA         22)       45       "Aggressive" (diffuse mixed, diffuse large cell, 30 I + II, 19 III + IVII         (23)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       S0 I + II, 19 III + IVII         (30)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       S0 I + II, 19 III + IVII         (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       S0 I + II, 19 III + IVII	. (24)       60       45 NS, 9 MC, 3 LP, 3 unclassifiable       25 II, 19 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         al. (21)       48       NA       11, 9 II, 7 III, 2 IV         25)       6       Aggressive by REAL/WHO criteria       21, 9 II, 7 III, 2 IV         26       12       11 diffuse large, 1 PTCL       NA         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + N       NA         22)       24       Aggressive by REAL/WHO criteria       NA         (23)       24       45       I angioimmunoblastic T-cell       NA         (23)       45       "Aggressive" (diffuse mixed, diffuse large cell, 30 I + II, 19 III + NI         . (23)       5       5 DLBCL       NA       NA         . (24)       7       5 MCL, 3 PTCL       NA         . (24)       5 MCL, 3 PTCL       NA       NA	9 MC, 3 LP, 3 unclassifiable 25 II, 19 II, 7 III, 2 IV NA Scher Predentia 25 II, 9 II, 7 III, 2 IV sive by REAL/WHO criteria 31, 5 II, 2 III, 2 IV SCL, 8 FL grade 3 19 1 + II, 35 III + IV NA 19 II + II, 35 III + IV NA 19 II + II, 35 III + IV NA 19 II + II, 19 III + IV sive by REAL/WHO criteria 10 I + II, 19 III + IV cell immunoblastic 1 - cell NA 19 II + IV SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA	Spacepen et al. (24)         60         45 NS, 9 MC, 3 LP, 3 unclassifiable         25 II, 16 IV         Stanford V or MOPP + ABV ± radiotherapy Werkmanuch et al. (23)         20         NA         1, 9 II, 7 III, 2 IV         Stanford V or MOPP + ABV, or BEACOPP ± radiotherapy ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy agreesive NHL           GPOH-HD 553         B         ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy agreesive NHL         ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy agreesive NHL         ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy agreesive NHL           Ge Vit et al. (25)         6         Aggreesive by REAL/WHO criteria         NA         Chemotherapy ± radiotherapy 3 I, 5 II, 2 III, 2 IV         Chemotherapy ± radiotherapy Chemotherapy ± radiotherapy 47         Chemotherapy ± radiotherapy 47 <t< td=""><td>cell fr</td><td>Spaepen et al. (24)         60         45 NS. 9 MC, 3 LP, 3 unclassifiable         25 II, 19 II, 7 III, 2 IV         Standord V or MOPP + ABV ± radiotherapy Weikmauch et al. (27)         48         ABV ± radiotherapy           Wickmann         al. (21)         48         NA         CHOPH 10 955         Factorbe + ABVD, or BEACOPP ± radiotherapy<sup>+</sup>           ggressive NHL         6         Aggressive by FEALWHO criteria         11, 9 II, 7 III, 2 IV         Chemotherapy ± radiotherapy           ggressive NHL         6         Aggressive by FEALWHO criteria         NA         Chemotherapy ± radiotherapy           de Writ et al. (25)         12         11 diffuse large         19 I + II, 35 II + IV         Chemotherapy ± radiotherapy           Jurveid et al. (25)         54         47 diffuse large         19 I + II, 35 III + IV         Chemotherapy ± radiotherapy           Jurveid et al. (27)         54         47 diffuse large         19 I + II, 35 III + IV         22 CHOP; 2 ProMACE-CytaBOM, 1 CNOP           Jurveid et al. (28)         54         45         Aggressive by FEALWHO criteria         NA         Chemotherapy ± radiotherapy           Mickosch et al. (29)         5         11 ngjoimmunoblastic         NA         Chemotherapy ± radiotherapy           Mickosch et al. (28)         5         5         01 BCL, 8 ALCL, 7 ALCL HD-IK         NA         Chemothe</td><td>Schaefer et al. (30)</td><td>18</td><td>17 NS, 1 MC</td><td>NA</td><td>NA</td></t<>	cell fr	Spaepen et al. (24)         60         45 NS. 9 MC, 3 LP, 3 unclassifiable         25 II, 19 II, 7 III, 2 IV         Standord V or MOPP + ABV ± radiotherapy Weikmauch et al. (27)         48         ABV ± radiotherapy           Wickmann         al. (21)         48         NA         CHOPH 10 955         Factorbe + ABVD, or BEACOPP ± radiotherapy <sup>+</sup> ggressive NHL         6         Aggressive by FEALWHO criteria         11, 9 II, 7 III, 2 IV         Chemotherapy ± radiotherapy           ggressive NHL         6         Aggressive by FEALWHO criteria         NA         Chemotherapy ± radiotherapy           de Writ et al. (25)         12         11 diffuse large         19 I + II, 35 II + IV         Chemotherapy ± radiotherapy           Jurveid et al. (25)         54         47 diffuse large         19 I + II, 35 III + IV         Chemotherapy ± radiotherapy           Jurveid et al. (27)         54         47 diffuse large         19 I + II, 35 III + IV         22 CHOP; 2 ProMACE-CytaBOM, 1 CNOP           Jurveid et al. (28)         54         45         Aggressive by FEALWHO criteria         NA         Chemotherapy ± radiotherapy           Mickosch et al. (29)         5         11 ngjoimmunoblastic         NA         Chemotherapy ± radiotherapy           Mickosch et al. (28)         5         5         01 BCL, 8 ALCL, 7 ALCL HD-IK         NA         Chemothe	Schaefer et al. (30)	18	17 NS, 1 MC	NA	NA	
al. (34)       20       NA       11, 91, 711, 21V         al. (21)       48       NA       NA         25)       6       Aggressive by REAL/WHO criteria       11, 91, 711, 21V         26)       12       11 diffuse large, 1 PTCL       NA         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + 11, 35 III + 1V         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + 11, 35 III + 1V         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + 11, 35 III + 1V         22)       24       Aggressive by REAL/WHO criteria       NA         (23)       24       Softerse mixed, diffuse large cell, 301 + 11, 19 III + 1VI         (23)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       Softerse large cell, 301 + 11, 19 III + 1VI         (30)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       Softer, 3 PTCL       NA	al. ( <i>21</i> ) 20 NA al. ( <i>21</i> ) 48 NA 25) 6 Aggressive by REAL/WHO criteria 25) 12 11 diffuse large, 1 PTCL 27 DLBCL, 8 FL grade 3 27 DLBCL, 8 FL grade 3 27 DLBCL, 8 FL grade 3 27 DLBCL, 8 FL grade 3 28 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 1 + II, 35 II, 2 II, 2 IV NA NA 28 27 DLBCL, 8 FL grade 3 20 1 + II, 35 II, 1 + N 28 27 DLBCL, 8 FL grade 3 28 27 0 LBCL, 8 ALCL, 2 diffuse mixed, 28 45 46 7 diffuse large cell, 19 1 + 1, 19 II + N 28 5 0 LBCL 29 5 0 LBCL, 8 ALCL, 7 ALCL HD-like, NA 5 MCL, 3 PTCL	sive by REAL/WHO criteria sive by REAL/WHO criteria ise large, 1 PTCL SCL, 8 FL grade 3 SCL, 8 FL grade 3 ise large cell, 4 ALCL, 2 diffuse mixed, gioimmunoblastic T-cell sive by REAL/WHO criteria sive by REAL/WHO criteria sive by REAL/WHO criteria Scive inffuse mixed, diffuse large cell, all + II, 19 III + IV <sup>II</sup> cell immunoblastic) SCL, 8 ALCL, 7 ALCL HD-like, SCL, 3 PTCL	Weihrauch et al. (34)         20         NA         11, 9 II, 7 III, 2 IV         ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy <sup>4</sup> Wickmann et al. (21)         48         NA         NA         GPOH-HD 95 <sup>5</sup> GPOH-HD 95 <sup>5</sup> Owickmann et al. (21)         6         Aggressive by REALWHO criteria         NA         GPOH-HD 95 <sup>5</sup> GPOH-HD 95 <sup>5</sup> Owickmann et al. (27)         12         11 diffuse large, 1 PTCL         NA         Chemotherapy ± radiotherapy           Foo et al. (26)         12         11 diffuse large, 1 PTCL         NA         Chemotherapy ± radiotherapy           Juweid et al. (22)         54         7 diffuse large, 1 PTCL         NA         Chemotherapy ± radiotherapy           Juweid et al. (22)         54         7 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + I, 35 III + IV         22 CHOP; 2 ProMACE-CytaBOM, 1 CNOP           Mikosch et al. (28)         24         Aggressive by REALWHO criteria         NA         Chemotherapy ± radiotherapy           Mikosch et al. (28)         5         24         Aggressive by REALWHO criteria         NA         Chemotherapy ± radiotherapy           Mikosch et al. (28)         5         18         NA         22 CHOP; 29 ProMACE-CytaBOM, 1 CNOP           Schaefer et al. (29)         5         5         Ditel, 1         NA	oell tr	Weihrauch et al. (34)         20         NA         11, 9 II, 7 III, 2 IV         ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy <sup>1</sup> Weiknauch et al. (21)         48         NA         Na         GPOH-HD B95           Weiknauch et al. (22)         6         Aggressive by FEAL/WHO criteria         NA         GPOH-HD B95           Foo et al. (25)         12         11 diffuse large, 1 PTCL.         31, 5 II, 2 IV         Chemotherapy ± radiotherapy           Jurnsleid et al. (22)         12         11 diffuse large, 1 PTCL.         31, 5 II, 2 IV         Chemotherapy ± radiotherapy           Jurnsleid et al. (22)         12         11 diffuse large, 1 PTCL.         31, 5 II, 2 IV         Chemotherapy ± radiotherapy           Jurnsleid et al. (22)         12         14 diffuse large, 68I, 4 ALCL, 2 diffuse large cell, 11, 19 III + NI         22 CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Mikosot et al. (23)         5         5 DBCL         NA         Chemotherapy ± radiotherapy           Mikosot et al. (23)         5         5 DBCL         NA         Chemotherapy ± radiotherapy           Schaefer et al. (29)         5         5 DBCL         NA         Chemotherapy ± radiotherapy           Schaefer et al. (29)         5         5 DBCL         NA         Chemotherapy ± radiotherapy           Schaefer et al. (29)         <	Spaepen et al. (24)	60		25 II, 19 III, 16 IV	Stanford V or MOPP + ABV ± radiotherapy	
al. (21)       48       NA       NA         25)       6       Aggressive by REAL/WHO criteria       NA         21       12       11 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 ll, 2 ll         21       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 ll         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lV         22)       24       Aggressive by REAL/WHO criteria       NA         (23)       24       Aggressive diffuse mixed, diffuse large cell, 30 l + ll, 19 ll + NI         (23)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         .(24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         .(24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA	<ul> <li>al. (21) 48 NA</li> <li>b) Aggressive by REAL/WHO criteria</li> <li>c) Afgressive by REAL/WHO criteria</li> <li>c) Afgressive interved, diffuse large cell, an unublastic</li> <li>c) Afgressive interved, diffuse large cell, an unublastic)</li> <li>c) Afgressive and a cliffuse large cell, an unublastic)</li> <li>c) Aggressive and a cliffuse large cell, an unublastic)</li> <li>c) Aggressive and a cliffuse large cell, and a cliffuse large cell, an unublastic)</li> <li>c) Aggressive and a cliffuse large cell, and a cliffuse large cell and a cliffuse</li></ul>	NA sive by REAL/WHO criteria ise large, 1 PTCL SCL, 8 FL grade 3 SCL, 8 FL grade 3 ise large cell, 4 ALCL, 2 diffuse mixed, gioimmunoblastic T-cell sive by REAL/WHO criteria sive by REAL/WHO criteria sive by REAL/WHO criteria Scive" (diffuse mixed, diffuse large cell, cell immunoblastic) SCL, 8 ALCL, 7 ALCL HD-like, SCL, 3 PTCL	Wickmann et al. (21)         48         NA         NA         GPOH-HD 955           geressive NHL         6         Agressive by REAL/WHO criteria         NA         Chemotherapy ± radiotherapy           de Wit et al. (26)         12         112         114 diffuse large, 1 PTCL         31, 5 II, 2 II, 2 IV         Chemotherapy ± radiotherapy           de Wit et al. (26)         12         12         14 diffuse large, 1 PTCL         31, 5 II, 2 II, 2 IV         Chemotherapy ± radiotherapy           Jurvaid et al. (27)         54         47 diffuse large cell, 4 ALCL, 2 diffuse mixed,         191 + II, 35 II + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Miknosch et al. (22)         24         Aggressive by REAL/WHO criteria         NA         Chemotherapy ± radiotherapy           Miknosch et al. (23)         24         Aggressive by REAL/WHO criteria         NA         CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Miknosch et al. (23)         24         Aggressive by REAL/WHO criteria         NA         Chemotherapy ± radiotherapy           Miknosch et al. (23)         54         47 diffuse mixed, diffuse large cell         301 + II, 19 III + IVI         Radiotherapy           Schaefer et al. (23)         5         5 DLBCL,         8 ALCL, 7 ALCL HD-IIKe,         NA           Schaefer et al. (24)         5         5	See Z Z	Wickmann et al. (21)         48         NA         NA         GPOH-HD 955           Bigressive NHL         6         Aggressive by FRALWHO criteria         NA         Chemotherapy ± radiotherapy           de Writ al. (25)         12         11 diffuse large al. 7 PTCL         31, 5 II, 2 IV         Chemotherapy ± radiotherapy           fee ot al. (26)         12         11 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Jurvied et al. (22)         54         4 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + IV         22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP           Mixosch et al. (22)         54         4 diffuse large cell, annuoblastic         NA         Chemotherapy ± radiotherapy           Mixosch et al. (22)         54         4 diffuse large cell, annuoblastic         NA         Chemotherapy ± radiotherapy           Mixosch et al. (22)         54         50 LBCL, R L, additerapy         NA         Chemotherapy ± radiotherapy           Mixosch et al. (23)         5         5         01 BCL, R L, additerapy         NA         Chemotherapy ± radiotherapy           Mixosch et al. (23)         5         5         01 BCL, NHO         NA         Chemotherapy ± radiotherapy           State of a 1 (22)         5         01 BCL, R L, additerapy         NA	Weihrauch et al. (34)	20	NA	1 I, 9 II, 7 III, 2 IV	ABVD, C-MOPP + ABVD, or BEACOPP ± radiotherapy <sup>‡</sup>	
<ul> <li>(31) 6 Aggressive by REAL/WHO criteria NA</li> <li>(31) 12 11 diffuse large, 1 PTCL</li> <li>al. (31) 35 27 DLBCL, 8 FL grade 3</li> <li>27 DLBCL, 8 FL grade 3</li> <li>27 DLBCL, 8 FL grade 3</li> <li>19 1 + II, 35 III + IV</li> <li>1 angioimmunoblastic T-cell</li> <li>(28) 24 Aggressive by REAL/WHO criteria</li> <li>(23) 45 "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI</li> <li>(23) 5 5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	<ul> <li>(37)</li> <li>(31)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(35)</li> <li>(37)</li> <li>(37)</li> <li>(35)</li> <li>(37)</li> <li>(37)</li> <li>(36)</li> <li>(37)</li> <li>(38)</li> <li>(37)</li> <li>(37)</li> <li>(38)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(37)</li> <li>(38)</li> <li>(37)</li> <li>(37)</li> <li>(38)</li> <li>(37)</li> <li>(37)</li> <li>(38)</li> <li>(39)</li> <li>(39)</li> <li>(39)</li> <li>(30)</li> <li>(30)<td>sive by REAL/WHO criteria NA use large, 1 PTCL 31, 5 II, 2 II, 2 IV SCL, 8 FL grade 3 SCL, 8 FL grade 3 Use large cell, 4 ALCL, 2 diffuse mixed, gioimmunoblastic T-cell NA sive by REAL/WHO criteria NA sive (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV<sup>II</sup> cell immunoblastic) NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 3 PTCL</td><td>ggressive NHL       MA       MA       Chemotherapy ± radiotherapy         de Wit et al. (25)       12       11 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 lN       Chemotherapy ± radiotherapy         Foo et al. (26)       12       11 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 ll       Chemotherapy ± radiotherapy         Jerusalem et al. (21)       35       27 DLBCL, 8 FL grade3       NA       Chemotherapy ± radiotherapy         Juweid et al. (22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lN       22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP         Mikosch et al. (23)       24       Aggressive by REALWHO criteria       NA       Chemotherapy ± radiotherapy         Mikosch et al. (23)       25       DLBCL       NA       Chemotherapy ± radiotherapy         Mikhaeel et al. (23)       5       DLBCL       NA       Chemotherapy only or CHOP ± radiotherapy         Schaefer et al. (23)       5       5 DLBCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (23)       5       5 MCL, 3 PLCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (24)       5       50 DLBCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (29)</td><td>sell tr</td><td>ggressive NHL 6 Magressive by FRAL/WHO criteria M NA Chemotherapy ± radiotherapy de Wit et al. (25) 6 Aggressive by FRAL/WHO criteria NA Chemotherapy ± radiotherapy to the content (25) 11, 2 ND Chemotherapy ± radiotherapy to the content (27) 11, 2 ND Chemotherapy ± radiotherapy ± tradiotherapy ± radiotherapy ± tradiotherapy ± tradiotherapy ± tradiotherapy ± radiotherapy ± radiotherapy ± radiotherapy ± radiotherapy ± tradiotherapy ± trad</td><td>Wickmann et al. (21)</td><td>48</td><td>NA</td><td>NA</td><td>GPOH-HD 95<sup>8</sup></td></li></ul>	sive by REAL/WHO criteria NA use large, 1 PTCL 31, 5 II, 2 II, 2 IV SCL, 8 FL grade 3 SCL, 8 FL grade 3 Use large cell, 4 ALCL, 2 diffuse mixed, gioimmunoblastic T-cell NA sive by REAL/WHO criteria NA sive (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> cell immunoblastic) NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 3 PTCL	ggressive NHL       MA       MA       Chemotherapy ± radiotherapy         de Wit et al. (25)       12       11 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 lN       Chemotherapy ± radiotherapy         Foo et al. (26)       12       11 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 ll       Chemotherapy ± radiotherapy         Jerusalem et al. (21)       35       27 DLBCL, 8 FL grade3       NA       Chemotherapy ± radiotherapy         Juweid et al. (22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lN       22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP         Mikosch et al. (23)       24       Aggressive by REALWHO criteria       NA       Chemotherapy ± radiotherapy         Mikosch et al. (23)       25       DLBCL       NA       Chemotherapy ± radiotherapy         Mikhaeel et al. (23)       5       DLBCL       NA       Chemotherapy only or CHOP ± radiotherapy         Schaefer et al. (23)       5       5 DLBCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (23)       5       5 MCL, 3 PLCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (24)       5       50 DLBCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (29)	sell tr	ggressive NHL 6 Magressive by FRAL/WHO criteria M NA Chemotherapy ± radiotherapy de Wit et al. (25) 6 Aggressive by FRAL/WHO criteria NA Chemotherapy ± radiotherapy to the content (25) 11, 2 ND Chemotherapy ± radiotherapy to the content (27) 11, 2 ND Chemotherapy ± radiotherapy ± tradiotherapy ± radiotherapy ± tradiotherapy ± tradiotherapy ± tradiotherapy ± radiotherapy ± radiotherapy ± radiotherapy ± radiotherapy ± tradiotherapy ± trad	Wickmann et al. (21)	48	NA	NA	GPOH-HD 95 <sup>8</sup>	
25)       6       Aggressive by REAL/WHO criteria       NA         12       11 diffuse large, 1 PTCL       31, 5 ll, 2 ll, 2 ll, 2 ll, 2 ll         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lV         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 19 l + ll, 35 ll + lV         22)       24       Aggressive by REAL/WHO criteria       NA         (23)       24       Aggressive '(diffuse mixed, diffuse large cell, 30 l + ll, 19 ll + NI         (23)       5       5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         .(24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         .(24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA	25)6Aggressive by REAL/WHO criteriaNAal. (31)351211 diffuse large, 1 PTCL31, 5 ll, 2 ll, 2 ll, 2 llal. (31)3527 DLBCL, 8 FL grade 3NA22)5447 diffuse large cell, 4 ALCL, 2 diffuse mixed,19 l + ll, 35 lll + lV22)24Aggressive by REAL/WHO criteriaNA(28)24Aggressive by REAL/WHO criteriaNA(23)24Aggressive '(diffuse mixed, diffuse large cell, 30 l + ll, 19 lll + lV).(23)55 DLBCLNA.(24)7350 DLBCL, 8 ALCL, 7 ALCL HD-like, NANA5 MCL, 3 PTCL5 MCL, 3 PTCLNA	sive by REAL/WHO criteria NA use large, 1 PTCL 31, 5 II, 2 II, 2 IV SCL, 8 FL grade 3 NA SCL, 8 FL grade 3 NA use large cell, 4 ALCL, 2 diffuse mixed, gioimmunoblastic T-cell NA sive by REAL/WHO criteria NA sive by REAL/WHO criteria 01 + II, 19 II + I/ <sup>II</sup> cell immunoblastic) NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA	de Wit et al. (25) 6 Aggressive by REAL/WHO criteria NA Chemotherapy ± radiotherapy Foo et al. (26) 12 II, 2 III, 2 II,	sell tr	de Wit et al. (25) 6 Aggressive by REAL/WHO criteria NA Chemotherapy ± radiotherapy Foo tal. (26) 12 11 diffuse large, 1 PTCL 31, 51, 2 III, 2 IV Chemotherapy ± radiotherapy Jerusalem et al. (31) 35 27 DLBCL, 8 FL grade 3 Juweid et al. (22) 14 diffuse large call, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV 22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP Juweid et al. (23) 45 47 diffuse large call, 4 ALCL, 2 diffuse mixed, 19 I + II, 35 III + IV 22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP Mikhaele et al. (23) 45 Aggressive by REAL/WHO criteria NA Chemotherapy ± radiotherapy Mikhaele et al. (23) 5 5 DLBCL and the mixed, fiftuse large cell, 30 I + II, 19 III + WI Radiotherapy only or CHOP ± radiotherapy Schaefer et al. (30) 5 5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxorubicin-containing regimen or UKCCSG protocol Schaefer et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxorubicin-containing regimen or UKCCSG protocol Got reliance and active assets and active and active and active assets) . Societing to Ann Arbor staging system. . Corording to	ggressive NHL					
12       11 diffuse large, 1 PTCL       31, 5 ll, 2 lll, 2 ll, 3 ll, 1	12       11 diffuse large, 1 PTCL       31, 5 ll, 2 lll, 2 ll, 2 lN         al. (31)       35       27 DLBCL, 8 FL grade 3       NA         22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed,       191 + ll, 35 lll + lN         228)       24       Aggressive by REAL/WHO criteria       NA         (28)       24       Aggressive by REAL/WHO criteria       NA         .(23)       45       "Aggressive" (diffuse mixed, diffuse large cell, 301 + ll, 19 lll + IV)         .(23)       5       5 DLBCL       NA         .(30)       5       5 DLBCL       NA         .(24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         .(24)       5 MCL, 3 PTCL       NA       NA	use large, 1 PTCL 31, 511, 211, 21V SCL, 8 FL grade 3 NA NA use large cell, 4 ALCL, 2 diffuse mixed, 191 + 11, 3511 + 1V gioimmunoblastic T-cell NA NA sive by REAL/WHO criteria NA Sive" (diffuse mixed, diffuse large cell, 301 + 11, 1911 + 1V <sup>II</sup> cell immunoblastic) NA Sive. (diffuse mixed, diffuse large cell, 301 + 11, 1911 + 1V <sup>II</sup> cell immunoblastic) NA Sicus ALCL, 7 ALCL HD-like, NA Sicus 301 + 11, 1911 + 10 <sup>II</sup>	Foo et al. (26)       12       11 diffuse large, 1 PTCL       3 I, 5 II, 2 IV       Chemotherapy ± radiotherapy         Jerusalem et al. (31)       35       27 DLBCL, 8 FL grade 3       NA       Chemotherapy ± radiotherapy         Juweid et al. (22)       54       47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV       22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP         Mikosch et al. (23)       24       Aggressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         Mikhaele et al. (23)       24       Aggressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         Mikhaele et al. (23)       5       5       Discreter et al. (20)       5       Discreter et al. (20)         Schaefer et al. (24)       5       5       DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA       NA         Spaepen et al. (24)       5       5       DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA       Dosorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Sochaefer et al. (24)       5       5       DLBCL, 3 PTCL       NA       Dosorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Sochaefer et al. (24)       5       5       DCL       2       Dosorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Sochaefer et al. (24)       5       Sochaef	cell tr	Foo et al. (26)       12       11 diffuse large, 1 PTCL       31, 5 II, 2 II, 2 IV       Chemotherapy ± radiotherapy         Jerusalem et al. (37)       35       27 DLBCL, 8FL grade 3       NA       Chemotherapy ± radiotherapy         Juweid et al. (22)       54       41 diffuse large cell, 4 ALCL, 2 diffuse mixed,       191 + II, 35 III + IV       22 CHOP, 29 P-CHOP, 2 ProMACE-CytaBOM, 1 CNOP         Mikosch et al. (27)       54       45       argoinmunoblastic 7-cell       NA       Chemotherapy ± radiotherapy         Mikosch et al. (28)       24       Aggressive by REALWHO criteria       NA       Chemotherapy ± radiotherapy         Mikosch et al. (29)       55       2.1 BLCL       NA       Chemotherapy ± radiotherapy         Mikosch et al. (29)       5       5 DLBCL       NA       Chemotherapy only or CHOP ± radiotherapy         Schaefer et al. (20)       5       5 DLBCL       NA       NA       Chemotherapy only or CHOP ± radiotherapy         Schaefer et al. (29)       5       5 DLBCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (20)       5       5 DLBCL       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Schaefer et al. (24)       5       5 DLBCL       NA       Doxorubicin-containing regimen or UKCCSG protocol	de Wit et al. (25)	9	Aggressive by REAL/WHO criteria	NA	Chemotherapy ± radiotherapy	
<ul> <li>27 DLBCL, 8 FL grade 3</li> <li>27 DLBCL, 8 FL grade 3</li> <li>54 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV</li> <li>1 angioimmunoblastic T-cell</li> <li>24 Aggressive by REAL/WHO criteria</li> <li>Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV<sup>II</sup></li> <li>1 arge cell immunoblastic)</li> <li>5 5 DLBCL</li> <li>7 3 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	<ul> <li>27 DLBCL, 8 FL grade 3</li> <li>47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV</li> <li>1 angioimmunoblastic T-cell</li> <li>Aggressive by REAL/WHO criteria</li> <li>MA</li> <li>Wagressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV<sup>II</sup></li> <li>arge cell immunoblastic)</li> <li>5 5 DLBCL</li> <li>5 0 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	SCL, 8 FL grade 3 NA Ise large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV gioimmunoblastic T-cell NA sive by REAL/WHO criteria NA sive idiffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> cell immunoblastic) NA CL, 8 ALCL, 7 ALCL HD-like, NA SCL, 8 ALCL, 7 ALCL HD-like, NA	Jerusalem et al. (31) 35 27 DLBCL, 8 FL grade 3 NA Chemotherapy ± radiotherapy Juweid et al. (22) 54 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV 22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP Mikosch et al. (28) 24 Aggressive by REAL/WHO criteria NA Chemotherapy ± radiotherapy ± radiotherapy Mikhaeel et al. (23) 45 Aggressive by REAL/WHO criteria NA Chemotherapy ± radiotherapy ± radiotherapy Schaefer et al. (30) 5 5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA NA CHOP ± radiotherapy 5 5 DLBCL NA NA NA NA NA CHOP ± radiotherapy 5 MCL, 3 PTCL ALCL, 7 ALCL HD-like, NA NA CHOP ± radiotherapy 5 MCL, 3 PTCL Strate and this systematic review.	Sell tr	Jerusalem et al. (31) 35 27 DLBCL, 8 FL grade 3 NA Chemotherapy ± radiotherapy 4 radiotherapy 1 radio 7 radiotherapy 1 radiotherapy 1 radiotherapy 4 radiotherapy 4 radiotherapy 1 radioth	Foo et al. (26)	12	11 diffuse large, 1 PTCL	3 I, 5 II, 2 III, 2 IV	Chemotherapy ± radiotherapy	
<ul> <li>54 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV</li> <li>1 angioimmunoblastic T-cell</li> <li>24 Aggressive by REAL/WHO criteria</li> <li>A</li> <li>5 <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup></li></ul>	<ul> <li>47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV</li> <li>1 angioimmunoblastic T-cell</li> <li>24 Aggressive by REAL/WHO criteria</li> <li>Aggressive by REAL/WHO criteria</li> <li>6 S DLBCL</li> <li>7 ALCL HD-like,</li> <li>NA</li> <li>5 MCL, 3 PTCL</li> </ul>	ise large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV gioimmunoblastic T-cell NA sive by REAL/WHO criteria NA ssive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> cell immunoblastic) NA SCL, 8 ALCL, 7 ALCL HD-like, NA SCL, 3 PTCL	Juweid et al. (22) 54 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + 1I, 35 III + IV 22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP 1 angioimmunoblastic T-cell NA Chemotherapy = radiotherapy Mikhaeel et al. (23) 24 Aggressive by REAL/WHO criteria NA Chemotherapy only or CHOP ± radiotherapy arge cell immunoblastic) NA Chemotherapy only or CHOP ± radiotherapy Schaefer et al. (30) 5 5 DLBCL NA NA Chemotherapy only or CHOP ± radiotherapy Schaefer et al. (30) 5 5 DLBCL NA NA Chemotherapy only or CHOP ± radiotherapy Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA NA Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA NA Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Chemotherapy only or CHOP ± radiotherapy for an order of this system or the system of this system.	Sell tr	Juweid et al. (22) 54 47 diffuse large cell, 4 ALCL, 2 diffuse mixed, 191 + II, 35 III + IV 22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP Mikosch et al. (28) 24 Aggressive by REALWHO criteria NA Chemotherapy ± radiotherapy i argointimunoblastic T-cell Mikhaele et al. (23) 45 "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI Radiotherapy only or CHOP ± radiotherapy argo cell immunoblastic) NA Chemotherapy only or CHOP ± radiotherapy Schaefer et al. (20) 5 5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxonbicin-containing regimen or UKCCSG protocol Spaepen et al. (24) 74 50 DLBCL, 7 ALCL HD-li	Jerusalem et al. (31)	35	27 DLBCL, 8 FL grade 3	NA	Chemotherapy ± radiotherapy	
<ol> <li>angioimmunoblastic T-cell</li> <li>Aggressive by REAL/WHO criteria</li> <li>Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV<sup>II</sup> large cell immunoblastic)</li> <li>5 DLBCL</li> <li>5 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ol>	1 angioimmunoblastic T-cell         24       Aggressive by REAL/WHO criteria       NA         45       "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI large cell immunoblastic)       5         5       5 DLBCL       NA         73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA         5 MCL, 3 PTCL       NA	gioimmunoblastic T-cell NA NA sive by REAL/WHO criteria NA ssive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> cell immunoblastic) NA SLL, 7 ALCL HD-like, NA SLL, 7 ALCL HD-like, NA	Mikosch et al. (28)       24       Aggressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         Mikhaeel et al. (23)       45       "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI       Radiotherapy ± radiotherapy         Mikhaeel et al. (23)       5       5 Clubic       NA       Chemotherapy only or CHOP ± radiotherapy         Schaefer et al. (30)       5       5 DLBCL       NA       NA         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         Vho met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Vho met inclusion criteria of this systematic review.       6 MCL, 3 PTCL       NA       NA       Na         Vho met inclusion criteria of this systematic review.       6 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)	Sell tr	Mikosch et al. (28)       24       1 angioimmunoblastic T-cell         Mikhaeel et al. (23)       45       "Aggressive by REAL/WHO criteria       NA         Mikhaeel et al. (23)       45       "Aggressive by REAL/WHO criteria       NA         Schaefer et al. (23)       5       5 DLBCL       NA       NA         Schaefer et al. (23)       5       5 DLBCL       NA       NA         Schaefer et al. (24)       73       5 DLBCL       NA       NA         Schaefer et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA       NA         No       NA       NA       NA       Doxrubicin-containing regimen or UKCCSG protocol         Mon       met inclusion criteria of this systematic review.       NA       NA       Doxrubicin-containing regimen or UKCCSG protocol         Mon       met inclusion criteria of this systematic review.       NA       Doxrubicin-containing regimen or UKCCSG protocol         Mon       met inclusion criteria of this systematic review.       NA       Doxrubicin-containing regimen or UKCCSG protocol         Mon       met inclusion criteria of this systematic review.       NA       Doxrubicin-containing regimen or UKCCSG protocol         Mon       met inclusion criteria of this systematic review.       NA       Doxrubicin-containing regimen or UKCCSG protocol <td>Juweid et al. (22)</td> <td>54</td> <td>47 diffuse large cell, 4 ALCL, 2 diffuse mixed,</td> <td>19 I + II, 35 III + IV</td> <td>22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP</td>	Juweid et al. (22)	54	47 diffuse large cell, 4 ALCL, 2 diffuse mixed,	19 I + II, 35 III + IV	22 CHOP, 29 R-CHOP, 2 ProMACE-CytaBOM, 1 CNOP	
<ul> <li>24 Aggressive by REAL/WHO criteria NA</li> <li>45 "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV<sup>II</sup> large cell immunoblastic)</li> <li>5 5 DLBCL</li> <li>73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	<ul> <li>24 Aggressive by REAL/WHO criteria NA</li> <li>45 "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI large cell immunoblastic)</li> <li>5 5 DLBCL</li> <li>73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	sive by REAL/WHO criteria NA ssive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> cell immunoblastic) NA SLL, 8 ALCL, 7 ALCL HD-like, NA SLL, 3 PTCL	Mikosch et al. (28)       24       Aggressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         Mikhaeel et al. (23)       45       "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI       Radiotherapy only or CHOP ± radiotherapy         Mikhaeel et al. (23)       5       5 S DLBCL       NA       NA         Schaefer et al. (30)       5       5 DLBCL       NA       NA         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA         No       NA       NA       NA         No       6 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Vho met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Korording to Ann Arbor staging system.       Containing regimen or without high-dose therapy followed by stem-cell transplantation.       Attemport relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation.		Mikosch et al. (28)       24       Aggressive by REAL/WHO criteria       NA       Chemotherapy ± radiotherapy         Mikhaeel et al. (23)       45       "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IVI       Radiotherapy only or CHOP ± radiotherapy         Mikhaeel et al. (23)       5       5 DLBCL       NA       NA       NA         Schaefer et al. (30)       5       5 DLBCL       NA       NA       NA         Schaefer et al. (30)       5       5 DLBCL       ALCL, 7 ALCL HD-like,       NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         Wo met inclusion criteria of this systematic review.       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         Wo met inclusion criteria of this systematic review.       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         Wo       6       Activation or tail or this systematic review.       NA       Doxorubicin-containing regimen or UKCCSG protocol         Wo       6       Activation or tail or this systematic review.       NA       Doxorubicin-containing regimen or UKCCSG protocol         Actoracording			1 angioimmunoblastic T-cell			
<ul> <li>45 "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV<sup>II</sup> large cell immunoblastic)</li> <li>5 5 DLBCL</li> <li>73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	<ul> <li>45 "Aggressive" (diffuse mixed, diffuse large cell, 30 I + II, 19 III + IV<sup>II</sup> large cell immunoblastic)</li> <li>5 5 DLBCL</li> <li>73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA</li> <li>5 MCL, 3 PTCL</li> </ul>	ssive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> cell immunoblastic) NA CL 8 ALCL, 7 ALCL HD-like, NA SCL, 8 PTCL	Mikhaeel et al. (23) 45 "Aggressive" (diffuse mixed, diffuse large cell, 301 + II, 19 III + IV <sup>II</sup> Radiotherapy only or CHOP ± radiotherapy bechaefer et al. (30) 5 5 DLBCL Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxorubicin-containing regimen or UKCCSG protocol of the met inclusion criteria of this systematic review.	Sell tr	Mikhaeel et al. (23)       45       "Aggressive" (diffuse mixed, diffuse large cell, 30 I + II, 19 III + IVI Radiotherapy only or CHOP ± radiotherapy large cell immunoblastic)         Na       NA       NA         Schaefer et al. (30)       5       5 DLBCL         Schaefer et al. (30)       5       5 DLBCL, SALCL, ALCL HD-like, NA       NA         No       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Schaefer et al. (30)       5       5 DLBCL, SALCL, 7 ALCL HD-like, NA       NA         Wo met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Wo met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       ALCL, 7 ALCL HD-like, NA       NA         Wo met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)         Wo       met inclusion criteria of this systematic review.       6       Secording to Ann Arbor staging system.         .coording to Ann Arbor staging system.       .conding to Ann Arbor staging system.       .conding to Ann Arbor staging system.         .coording to Ann Arbor staging system.       .condition the arbor stage therapy with or without high-dose therapy followed by stem-cell transplantation.       .condition ton total peravice and adolescents (35).	Mikosch et al. (28)	24	Aggressive by REAL/WHO criteria	NA	Chemotherapy ± radiotherapy	
large cell immunoblastic)       5       5 DLBCL         73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA         5 MCL, 3 PTCL       5 MCL, 3 PTCL	large cell immunoblastic) 5 5 DLBCL 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA 5 MCL, 3 PTCL	cell immunoblastic) SL 8 ALCL, 7 ALCL HD-like, NA SL, 3 PTCL	Schaefer et al. (30)       5       5 DLBCL       NA       NA         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         Who met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol	cell tr	Schaefer et al. (30)       5       5 DLBCL       NA       NA         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       NA       Doxorubicin-containing regimen or UKCCSG protocol         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA       Doxorubicin-containing regimen or UKCCSG protocol         Vibro met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol         Vibro met inclusion criteria of this systematic review.       5 MCL, 3 PTCL       NA       Doxorubicin-containing regimen or UKCCSG protocol         Vibro met inclusion criteria of this systematic review.       6 MCL, 3 PTCL       ALCL ALCL HD-like, NA       NA         Vibro met inclusion criteria of this systematic review.       16 Model attric cases)       (pediatric cases)       (pediatric cases)         Vibro met inclusion criteria of this systematic review.       16 Model attric cases)       (pediatric cases)       (pediatric cases)         Vibro met inclusion criteria of this systematic review.       16 Model attric cases)       16 Model attric cases)       (pediatric cases)         Iceating to Ann Arbor staging system.       16 Model attric cases)       16 Model attric cases)       16 Model attric cases)       16 Model attric cases)         Iceating to Ann Arbor staging system.       16 Model attric cases       16 Model	Mikhaeel et al. (23)	45	"Aggressive" (diffuse mixed, diffuse large cell,	30 I + II, 19 III + IV <sup>II</sup>	Radiotherapy only or CHOP ± radiotherapy	
5 5 DLBCL NA 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA 5 MCL, 3 PTCL	5 5 DLBCL NA 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA 5 MCL, 3 PTCL	DL NA SCL, 8 ALCL, 7 ALCL HD-like, NA DL, 3 PTCL	Schaefer et al. (30) 5 5 DLBCL NA NA Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases) Who met inclusion criteria of this systematic review.	cell tr	Schaefer et al. (30)       5       5 DLBCL       NA       NA         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         No       met inclusion criteria of this systematic review.       6 MCL, 3 PTCL       (pediatric cases)         No       met inclusion criteria of this systematic review.			large cell immunoblastic)			
73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA 5 MCL, 3 PTCL	73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA 5 MCL, 3 PTCL	3CL, 8 ALCL, 7 ALCL HD-like, NA 3L, 3 PTCL	Spaepen et al. (24) 73 50 DLBCL, 8 ALCL, 7 ALCL HD-like, NA Doxorubicin-containing regimen or UKCCSG protocol 5 MCL, 3 PTCL (pediatric cases) Who met inclusion criteria of this systematic review.	cell tr	Spaepen et al. (24)       73       50 DLBCL, 8 ALCL, 7 ALCL HD-like,       NA       Doxorubicin-containing regimen or UKCCSG protocol         Vio       5 MCL, 3 PTCL       (pediatric cases)         Vio       (pediatric cases)         According to Ann Arbor staging system.       (pediatric cases)         Teatment strategy for HD in children and adolescents (35).       If the apple of the rapy followed by stem-cell transplantation.         Treatment strategy for HD in children and adolescents (35).       To an abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy.         LCL = anaplastic large ell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CEP         LCL = anaplastic larger of lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CEP	Schaefer et al. (30)	5	5 DLBCL	NA	NA	
			Who met inclusion criteria of this systematic review. According to Ann Arbor staging system. Eicht relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation.	Who met inclusion criteria of this systematic review. According to Ann Arbor staging system. Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. Featment strategy for HD in children and adolescents (35).	<sup>Vho</sup> met inclusion criteria of this systematic review. <sup>viccording to Ann Arbor staging system. <sup>viccording to Ann Arbor stage therapy with or without high-dose therapy followed by stem-cell transplantation. <sup>viccording to Ann Pin children and adolescents (35). <sup>viccording to Ann total participants, not limited to patients who were evaluated with PET at end of therapy. <sup>viccording to Ann total participants, not limited to patients who were evaluated with PET at end of therapy. <sup>viccording to Ann total participants, not limited to patients who were evaluated with PET at end of therapy. <sup>viccording to Ann total participants, not limited to patients who were evaluated with PET at end of therapy. <sup>viccording to Ann total participants, not limited to patients who were evaluated with PET at end of therapy. <sup>viccording to Annota and adolescents (35). <sup>viccording to Annota adolescents (35). <p< sup=""></p<></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup>	Spaepen et al. (24)	73	50 DLBCL, 8 ALCL, 7 ALCL HD-like, 5 MCL, 3 PTCL	NA	Doxorubicin-containing regimen or UKCCSG protocol (pediatric cases)	
*Who met inclusion criteria of this systematic review. <sup>1</sup> According to Ann Arbor staging system. <sup>†</sup> Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. <sup>‡</sup> Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. <sup>‡</sup> Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. <sup>‡</sup> Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. <sup>‡</sup> Treatment strategy for HD in children and adolescents (35). <sup>B</sup> Data abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy. ALCL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CEP = ALCL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BCL = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone; CEP = ALCL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BCL = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone; CEP = ALCL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BCL = bleomycin, etoposide, doxorubicin, cyclophosphamide, wincristine, procarbazine, prednisone; CNOP = cyclophosphamide, wincristine, procarbazine, prednisone; CEP = ALCL = anaplastic large cell lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sciences; ProMACE- MCD = ALCL = anaple cell lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sciences; ProMACE- ALCL = anaple cell lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sciences; ProMACE- ALCL = anaple cell lymphocyte predominance; MC = mixed cellulari	According to Ann Arbor staging system. Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. Treatment strategy for HD in children and adolescents (35). Data abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy. LCL = anaplastic large cell lymphona; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednison LCL = anaplastic large cell lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; FL = homon; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; FL	reatment strategy for HD in children and adolescents (35). ata abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy. .CL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CE bu, etoposide, prednimustine; C-MOPP = cyclophosphamide, vincristine, procarbazine, prednisone; CNOP = cyclophosphamide, mitoxantrone, vincristine, prednisone; FL = follic homa; LD = lymphocyte depleted; LP = lymphocyte predoninance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; ProMA	-CL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CEF U, etoposide, prednimustine; C-MOPP = cyclophosphamide, vincristine, procarbazine, prednisone; CNOP = cyclophosphamide, mitoxantrone, vincristine, prednisone; FL = follic homa; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; ProMA	whoma; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = not durant celerosis; ProMAC		IBUM = preanisone, cyc )P; Stanford V = doxorut	ciopnospnamide, c oicin, vinblastine, r	ioxorubicin, etoposide, cytarabine, pieomycin, vi nechlorethamine, vincristine, bleomycin, etoposic	ncristine, methotrexate de, prednisone; UKSCC	רוכב = peripreral ו-כפו ואימאסימים; א-כאסר = הועאותום p G = United Kingdom children cancer study group; WHO = Wo	
<ul> <li>The met inclusion criteria of this systematic review.</li> <li>Coording to Ann Arbor staging system.</li> <li>Ciscording to Ann Arbor staging system.</li> <li>Ciscording to Ann Arbor staging system.</li> <li>Cistor a strategy for HD in children and adolescents (<i>35</i>).</li> <li>Cistor a subtracted from total participants, not limited to patients who were evaluated with PET at end of therapy.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants, not limited to patients.</li> <li>Cistor a subtracted from total participants.</li> <li>Cistor a subtraction.</li> <li>Cistor a subtraction.</li> <li>Cistor a subtracted from total participants.</li> <li>Cistor a subtracted from total participants.</li> <li>Cistor a subtracted from total partition.</li> <li>C</li></ul>	<sup>†</sup> According to Ann Arbor staging system. <sup>‡</sup> Eight relapsed cases (excluded) received salvage therapy with or without high-dose therapy followed by stem-cell transplantation. <sup>\$T</sup> reatment strategy for HD in children and adolescents (35). <sup>¶</sup> Treatment strategy for HD in children and adolescents (35). <sup>¶</sup> Data abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy. <sup>¶</sup> CL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednison ALCL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, wincristine, prednisone; FL = (ND, etoposide, prednimustine; C-MOPP = cyclophosphamide, vincristine, procarbazine, prednisone; MCL = mantle cell lymphoma; NA = not available; NS = noclular sclerosis; F (Mphoma; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = noclular sclerosis; F (CABOM = prednisone, cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate; PTCL = peripheral T-cell lymphoma; R-CHOP = ritux CHOP; Stanford V = doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone; UKSCCG = United Kingdom children cancer study group; WHC	reatment strategy for HD in children and adolescents (35). ata abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy. .CL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CE U, etoposide, prednimustine; C-MOPP = cyclophosphamide, vincristine, procarbazine, prednisone; CNOP = cyclophosphamide, mitoxantrone, vincristine, prednisone; FL = follic homa; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; ProMA BOM = prednisone, cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate; PTCL = peripheral T-cell lymphoma; R-CHOP = rituximab I P: Stanford V = doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone; UKSCG = United Kingdom children cancer study group; WHO = W	-CL = anaplastic large cell lymphoma; BCL = B-cell lymphoma; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; CEI U, etoposide, prednimustine; C-MOPP = cyclophosphamide, vincristine, procarbazine, prednisone; CNOP = cyclophosphamide, mitoxantrone, vincristine, prednisone; FL = follic homa; LD = lymphocyte depleted; LP = lymphocyte predominance; MC = mixed cellularity; MCL = mantle cell lymphoma; NA = not available; NS = nodular sclerosis; ProMA BOM = prednisone, cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate; PTCL = peripheral T-cell lymphoma; R-CHOP = rituximab p P: Stanford V = doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone; UKSCG = United Kindom children cancer study group; WHO = W	y more supported and the second structure of the second struct of the second structure of the second s	IBOM = prednsone, cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate, PTCL = peripheral T-cell lymphoma; H-CHOP = rituximab p DP: Stanford V = doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone; UKSCG = United Kingdom children cancer study group; WHO = W						

A Systematic Review • Terasawa et al. 17




**FIGURE 1.** Sensitivity and specificity for HD (A and B) and aggressive NHL (C and D). Size of square plotting symbol is proportional to sample size (for sensitivity, number of patients who relapsed; for specificity, number of patients in remission) for each study. Horizontal lines are 95% confidence intervals. One study (Foo et al.) is omitted for sensitivity for HD because there were no cases of relapse.

external validities, respectively, of the test results. The detailed results of the quality assessment can be found in the Supplemental Appendix.

# DISCUSSION

This systematic review showed that the reported sensitivities and specificities of <sup>18</sup>F-FDG PET to assess residual



**FIGURE 2.** ROC plotting and summary ROC curve of <sup>18</sup>F-FDG PET for HD and aggressive NHL. Individual study estimates of sensitivity and 1 – specificity are shown for posttherapy evaluation and residual mass evaluation of HD (A and B) and aggressive NHL (C and D). Size of each circle is proportional to sample size for each study (all study participants). Solid crescent boundary represents 95% confidence region for summary sensitivity and specificity.

disease for patients with HD who completed first-line chemo- or chemoradiotherapy had large between-study heterogeneity. In addition, the summary ROC curves and confidence regions for sensitivity and specificity showed similar and good overall diagnostic accuracy irrespective of the presence of a visible residual mass on conventional imaging modalities such as CT or MRI. For aggressive NHL, although our review showed a relatively stable high specificity and variable sensitivity, there were too few studies to calculate a reliable overall diagnostic accuracy. Many potential factors may explain the heterogeneity. For test characteristics, differences in the type of PET scanner, in the timing of PET after the completion of therapy, in positive test criteria, and in the clinical experience of the interpreters are relevant. For patient characteristics, several differences should be considered: in the type of histology, especially for aggressive NHL (e.g., DLBCL vs. other aggressive NHLs); in therapeutic strategy (e.g., chemotherapy vs. combinedmodality therapy); in the presence or absence of a visible residual mass on conventional imaging tests; and in relapse risk groups, such as the international prognostic score for advanced-stage HD (36) or the international prognostic index for aggressive NHL (8). For study characteristics, differences such as method of patient selection (e.g., prospective vs. retrospective), type and application of a reference standard, and patient follow-up have been reported to affect the variability of sensitivity and specificity (9,37). Because the available data were limited, we could not identify specific factors that explain the heterogeneity, which should be further addressed in future studies. Although the reported positive PET criteria appeared almost identical in all HD studies, the large crescent shape of the confidence regions implies a negative correlation between sensitivity and specificity across the included studies, suggesting that a variation in threshold may partially explain the between-study heterogeneity.

Our study had several important limitations. Because we selected only those studies for which pertinent data were available, several important investigations (some of which were included in the previous metaanalysis) may have been excluded. Also, because most data were derived from retrospective studies with poor-quality design and reporting, our conclusions are subject to the bias and variations in the original studies (*37*). In addition, our review included only a single study in which patients with DLBCL received rituximab in addition to CHOP (*22*). Because the combination of rituximab with CHOP is a current standard therapy (*38*), our results may be less applicable to clinical practice. Further, we included only a single study (*30*) that used a relatively new and promising additional technique—PET/CT—that may overcome the current technical limitations of PET (*39*).

In the recently revised consensus recommendations, <sup>18</sup>F-FDG PET has become an important component of posttherapy response assessments in clinical trials for HD and DLBCL (40). Although the currently available data have limitations, our systematic review would probably support the clinical relevance of the response criteria for high-risk HD; incomplete response defined by positive PET findings would have an excellent ability to predict relapse irrespective of whether a residual tumor mass is found on conventional imaging. For favorable-risk HD, patients labeled as incomplete responders after first-line therapy should still have a moderate possibility of long-term remission. Thus, clinical investigators adopting the recommendations into therapeutic efficacy trials would need to decide how to manage patients in this category before implementing the trials. For DLBCL and other aggressive NHLs, our results based on the limited clinical evidence would not suffice to support the criteria, and further research is necessary to validate them.

Our review shows that currently available data do not suffice to answer the phase 3 question of diagnostic accuracy studies: What is the diagnostic accuracy of <sup>18</sup>F-FDG PET for posttherapy response assessment of malignant lymphoma? (*41*). Reliable clinical evidence is especially limited for aggressive NHL. Further investigation should include prospective diagnostic accuracy studies (phase 3) of PET or

PET/CT that adopt a more rigorous research methodology. We propose that, ideally, diagnostic accuracy studies should accompany prospective clinical trials to answer efficacy questions. Data on additional therapy, such as involved-field radiotherapy or high-dose chemotherapy with autotransplantation, for posttherapy PET-positive patients are limited. Before the routine clinical implementation of a treatment strategy based on posttherapy PET findings, randomized studies should assess the impact on patients' clinical outcomes, if appropriate (phase 4) (*41*). Also, determination of the cost-effectiveness of treatment strategies adopting PET is necessary to allow a better understanding of the role of posttherapy PET.

# CONCLUSION

The currently available data show that <sup>18</sup>F-FDG PET has good overall accuracy in detecting residual disease in patients with HD who have completed first-line therapy. The current literature has methodologic weaknesses that may overestimate accuracy. Because data from original studies are limited, our review could not find robust evidence to answer the question of whether clinicians should routinely use PET to assess the posttherapeutic response, suggesting that they should be cautious about making clinical decisions based solely on a PET result.

## ACKNOWLEDGMENTS

We thank Maike de Wit, MD, Jerusalem Guy, MD, Malik Juweid, MD, Katalin Keresztes, MD, Peter Mikosch, MD, Heidy Mocikov, MD, Robert Pichler, MD, Niklaus Schaefer, MD, and Martin Weihrauch, MD, for providing the data on their original work; Yinghua Li, MD, and Leo Kawaguchi, MD, for assistance in translating Chinese- and Germanlanguage publications; Jonathan Deeks, PhD, Kengo Ito, MD, and Kazuo Kubota, MD, for helpful comments; Petra Macaskill, PhD, for providing statistical programs; and Bruce Cheson, MD, and Joseph Lau, MD, for reviewing the manuscript. Part of this work was supported by Grant-in-Aid 15-2 for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan, by the Japanese Society of Nuclear Medicine, and by Nihon Medi-Physics Corporation Limited.

## REFERENCES

- Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 1988;6:940–946.
- Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253.
- Meyer RM, Ambinder RF, Stroobants S. Hodgkin's lymphoma: evolving concepts with implications for practice. *Hematology Am Soc Hematol Educ Program.* 2004:184–202.
- Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. *J Nucl Med.* 2001;42(suppl): 1S–93S.
- Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol. 2004;126:772–784.

- Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol. 2004;22:4147–4156.
- Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. <sup>18</sup>F-Fluoro-deoxyglucose positron emission tomography for posttreatment evaluation of malignant lymphoma: a systematic review. *Haematologica*. 2006;91:522–529.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329: 987–994.
- Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003;138:40–44.
- Schelbert RS, Hoh CK, Royal HD, et al. Society of Nuclear Medicine procedure guideline for tumor imaging using F-18 FDG, version 2.0 [SNM Web site]. 1999. Available at: http://interactive.snm.org/index.cfm?PageID=772&RPID=969. Accessed October 18, 2007.
- Kent DL, Haynor DR, Larson EB, Deyo RA. Diagnosis of lumbar spinal stenosis in adults: a metaanalysis of the accuracy of CT, MR, and myelography. *AJR*. 1992;158:1135–1144.
- Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol.* 2003;3:25.
- Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. *Stat Med.* 2001;20:2865–2884.
- Macaskill P. Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol. 2004;57:925–932.
- Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. *Biostatistics*. 2007;8:239–251.
- Filmont JE, Yap CS, Ko F, et al. Conventional imaging and 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease. *Mol Imaging Biol.* 2004;6:47–54.
- Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. *Leuk Lymphoma*. 2004;45:85–92.
- Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using <sup>18</sup>F-FDG in Hodgkin's disease for posttreatment evaluation. *J Nucl Med.* 2003; 44:1225–1231.
- Rigacci L, Castagnoli A, Dini C, et al. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep. 2005;14:1209–1214.
- 20. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? *Br J Haematol.* 2001;115:272–278.
- Wickmann L, Luders H, Dorffel W. 18-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations [German]. *Klin Padiatr.* 2003;215:146–150.
- Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. *J Clin Oncol.* 2005; 23:4652–4661.

- Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with CT. *Leuk Lymphoma*. 2000;39:543–553.
- 24. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([<sup>18</sup>F]FDG) after firstline chemotherapy in non-Hodgkin's lymphoma: is [<sup>18</sup>F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414–419.
- de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Wholebody positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. *Ann Oncol.* 1997;8(suppl):57–60.
- Foo SS, Mitchell PL, Berlangieri SU, Smith CL, Scott AM. Positron emission tomography scanning in the assessment of patients with lymphoma. *Intern Med* J. 2004;34:388–397.
- 27. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using <sup>18</sup>F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. *Blood.* 1999;94: 429–433.
- Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, et al. Accuracy of whole-body <sup>18</sup>F-FDP-PET for restaging malignant lymphoma. *Acta Med Austriaca*. 2003; 30:41–47.
- Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. *Ann Oncol.* 2000;11(suppl):147–150.
- Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? *Radiology*. 2004;232:823–829.
- Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by wholebody positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 2003;14:123–130.
- Keresztes K, Lengyel Z, Devenyi K, Vadasz G, Miltenyi Z, Illes A. Mediastinal bulky tumour in Hodgkin's disease and prognostic value of positron emission tomography in the evaluation of post-treatment residual masses. *Acta Haematol.* 2004;112:194–199.
- 33. Mocikova H, Markova J, Belohlavek O, et al. Cas Lek Cesk. 2004;143:476-479.
- 34. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using <sup>18</sup>F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. *Blood.* 2001;98:2930–2934.
- 35. Dorffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. *Klin Padiatr.* 2003;215:139–145.
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506–1514.
- Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. *Ann Intern Med.* 2004;140:189–202.
- 38. Cheson BD. What is new in lymphoma? CA Cancer J Clin. 2004;54:260-272.
- Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(suppl):S117–S127.
- Cheson BD, Pfistner B, Juweid ME, et al. The International Harmonization Project on Lymphoma: revised response criteria for malignant lymphoma. *J Clin* Oncol. 2007;25:579–586.
- Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002; 324:539–541.